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1. Introduction 
1.1. Adenylyl cyclases 
1.1.1. AC isoforms 
Adenylyl cyclases (ACs) convert adenosine 5‟-triphosphate (ATP) to pyrophosphate and 
cyclic adenosine 3‟,5‟-monophosphate (cAMP), a second messenger that plays an important 
role in many different biological systems. The physiological activity of ACs is mainly 
regulated by G protein-coupled receptors (GPCRs) that are located in the plasma membrane 
and induce a GPCR-mediated signaling cascade in the cell. The term already indicates that 
GPCRs couple to G proteins, either to stimulatory G proteins, such as Gs, or to inhibitory G 
proteins, such as Gi. These proteins interact directly with AC and via activation cAMP is 
produced. Generation of cAMP influences a variety of cellular responses, such as 
embryogenesis (Bellen et al., 1987), hormone secretion (Dyachok et al., 2008), regulation of 
vascular smooth muscle (Hardman, 1984), cardiac contraction (Okumura et al., 2003a), 
olfaction as well as learning and memory (Wang and Storm, 2003). 
In humans, one soluble and nine membrane-bound AC isoforms are responsible for cAMP 
production (Buck et al., 1999; Hanoune and Defer, 2001; Kamenetsky et al., 2006). The 
unique soluble AC isoform (sAC) is not further discussed here, but it should be mentioned 
that this enzyme does not have membrane domains and is not regulated by G proteins, but 
stimulated by calcium and bicarbonate. It resembles cyanobacterial AC and plays a role in 
sperm motility and fertilization. Based on differences in the regulatory properties of 
membranous AC (mAC), they can be classified into four different categories: 
  ACs 1, 3 and 8 are stimulated by Ca2+/calmodulin (CaM) (class I);  
  ACs 2, 4 and 7 are stimulated by Gβ (class II); 
  ACs 5 and 6 constitute class III and are Gi/Ca
2+ inhibited and  
  AC 9 is the only member of class IV, because it is the only AC isoform that is not 
activated by forskolin (FS).  
FS is a natural diterpene, derived from the roots of Coleus forskohlii, an Indian plant and it is 
the most effective direct activator of ACs 1-8. Unfortunately, ACs are expressed only at low 
levels, and there is a lack of isoform-specific antibodies. Therefore, tissue distribution is 
detected mainly via PCR and Northern blotting, but also using functional assays, such as the 
AC activity assay (Sunahara et al., 1996; Hanoune and Defer, 2001; Göttle et al., 2009). 
Another possibility to comprehend the role and function of individual AC isoforms was 
achieved by changing the gene level of AC isoforms in knockout (KO) and overexpression 
studies (Schaefer et al., 2000; Yan et al., 2007; Sadana and Dessauer, 2009). Most cells 
express not only one single AC isoform. But some AC isoforms have a specific expression 
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pattern, and a physiological role can be assigned due to their localization. ACs 1 and 8 are 
associated to learning and memory, AC 3 plays a role in olfaction and ACs 5 and 6 regulate 
cardiac contractility (Table 1).  
 
 
Table 1. Expression pattern and physiological role of mACs and sAC. Specific physiological roles and 
expression levels were identified, using the above mentioned techniques (Sadana and Dessauer, 2009).  
Isoform Expression in 
tissue 
Physiological 
roles 
Genetic approach 
AC 1 brain, adrenal medulla 
learning, memory, 
synaptic plasticity, 
opiate withdrawal 
AC 1
-/-
 mice:  LTP,  pain response,  
 neuronal excitotoxicity,  withdrawal 
behavior,  ethanol sedation 
Overexpression: enhanced memory 
AC 2 
brain, lung, skeletal 
muscle, heart 
arrest of cell 
proliferation, synaptic 
plasticity 
 
AC 3 
olfactory epithelium, 
pancreas, brain, heart, 
lung, testis 
olfaction, sperm 
function 
AC 3
-/-
 mice:  odorant-induced signaling, 
 pheromone detection 
AC 4 no specific expression 
mood disorders, 
depression, photo 
reception 
 
AC 5 
heart, striatum, kidney, 
liver, lung, testis, adrenal  
cardiac contraction, 
motor coordination, 
opiate dependency, 
pain responses 
AC 5
-/-
 mice:  life span,  age-induced 
myopathy,  pain response, abnormal 
coordination,  morphine response 
Overexpression:  basal AC activity  
AC 6 
heart, kidney, liver, lung, 
brain, testis, skeletal 
muscle, adrenal 
cardiac contraction  
AC 6
-/-
 mice:  stimulated AC activity 
Overexpression:  response to  catechol-
amine, but no histological abnormalities   
AC 7 brain, platelets 
ethanol dependency, 
depression 
Overexpression:  morphine tolerance,    
 ethanol effect 
AC 8 
brain, lung, pancreas, 
testis, adrenal 
learning, memory, 
synaptic plasticity , LTP, 
opiate withdrawal 
AC 8
-/-
 mice:  LTP,  withdrawal 
behavior,  ethanol consumption 
AC 9 
no specific expression 
(eg. brain-hippocampus) 
polymorphism relevant 
in asthma treatment, 
learning, memory 
AC 9 gene deletion is embryonically lethal 
sAC 
testis, but detected in all 
tissues 
sperm capazitation, 
fertilization 
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It is important to understand that some AC isoforms have very similar physiological roles. 
As already mentioned AC 1 which is primarily expressed in brain, particularly in 
hippocampus, neocortex, entorhinal cortex and cerebellar cortex, is most likely connected to 
learning and memory, together with AC 8. Mice having a gene deletion of AC 1 showed 
normal growth and unchanged motor behavior and lifespan, but decreased Ca2+ stimulated 
activity in brain, decreased long-term potentiation (LTP) and deficiency in spatial memory 
(Wu et al., 1995). However, abnormalities in LTP could be reversed by FS, indicating that 
another AC isoform - most likely AC 8 - also contributes to these effects. Furthermore, ACs 1 
and 8 mediate morphine response. These two enzymes are quite similar in their regulatory 
profile, because they are, together with AC 3, regulated by Ca2+-bound CaM. However, ACs 
1 and 8 are mainly stimulated by direct binding of CaM to a CaM binding site, whereas AC 3 
is inhibited via CaM-dependent protein kinase II (Kamenetsky et al., 2006). 
 
Regulation of ACs can vary between the different isoforms, but all of the transmembrane 
isoforms are stimulated by Gs. Golf is also a stimulatory G protein predominantly expressed 
in olfactory tissue and it also activates AC. Gi inhibits only some of the AC isoforms, such as 
ACs 5 and 6, but also CaM stimulated AC 1. The Gβ-subunit can be either stimulatory (group 
II and III) or inhibitory (group I). ACs are further regulated by divalent cations. The presence 
of Mn2+ and Mg2+ stimulates the enzyme, but submicromolar concentrations of free Ca2+ 
inhibit ACs 5 and 6. In contrast, high, non-physiological concentrations of Ca2+ inhibit all AC 
isoforms, mainly by competition with Mg2+ for binding to the catalytic site. In a feedback 
mechanism ACs are influenced by protein kinases (PKs). PKA inhibits ACs 5 and 6 by direct 
phosphorylation of the cytosolic domain. PKC can be stimulatory (AC 1; PKC and AC 7; 
PKC/ and AC 5) or inhibitory (PKC and AC 4; PKC /PKC and AC 6). Additional 
kinases, such as tyrosine kinases, regulate indirectly AC activity which is not discussed here 
in more detail. Further regulation of ACs was shown by studying the interaction with different 
other proteins, such as Snapin or A-kinase anchoring protein (AKAP79), indicating high 
diversity of regulation (Beazely and Watts, 2006). 
 
Even though we already know quite a lot about the differential expression pattern and 
regulation of ACs 1-9, there are still many important questions: why do we have 10 different 
AC isoforms, and is it possible to activate or inhibit specific isoforms selectively? The search 
for isoform-specific AC inhibitors/activators may further help in characterization of the 
physiological role of single AC isoforms and could be used to identify new 
pharmacotherapeutic targets. In several studies it was shown that substrate affinity and 
selectivity of AC inhibitors and activators are different for some AC isoforms (Gille et al., 
2004; Pinto et al., 2009).  
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One possibility to characterize the different AC isoforms was the expression of full-length 
isoforms in mammalian and insect cells, but this was hampered by the non-availability of 
functional and pure protein and non-specificity of AC antibodies. The other possibility was the 
expression of the two functionally active catalytic domains C1 and C2 in Escherichia coli 
(Dessauer et al., 1997). With these soluble proteins in hand biochemical, kinetic and 
structural studies became possible.  
1.1.2. AC structure 
The following chapter will focus on the complex structure of mammalian transmembrane 
ACs (Krupinski et al., 1989). They consist of: 
 a short variable cytosolic N-terminus, that is highly divergent and plays an important  
role in regulation (e.g. phosphorylation by PKC to inhibit AC 6; stimulation of ACs 
5/6 by Gβ),  
 two hydrophobic transmembrane domains (M1 and M2) and  
 two cytosolic domains, namely C1 and C2, that form the catalytic center ( 40 kDa). 
 
The membrane spans are not important for catalysis, but they do play a role for a close 
location of C1 and C2. The N-terminal and C-terminal part of C1 and C2, referred to as C1b 
and C2b, show the highest diversity among the different isoforms and also by comparing 
different species. Within both cytosolic domains are  230 amino acids (AA) present that are 
responsible for catalysis. They are named C1a and C2a domains and their sequence is 
roughly 40% identical. The sequence homology of C1a and C2a of ACs 1, 2 and 5 is quite 
high. Therefore, even heterologous combinations of the two intracellular domains from 
different species and different isoforms can form a stable and active complex with each 
other. This was used  13 years ago to characterize the catalytic domains by purification of 
C1a domain of AC 5 and C2a domain of AC 2 and subsequent analysis of the crystal 
structure of these two soluble domains (Tesmer et al., 1997). Since then, this structure is 
used as the general functional model for mACs (Figure 1 B, Protein Data Bank 1AZS).  
Looking at the structure we can see that the interface between the two domains is 
pseudosymmetrical. The crystal structure was obtained by cocrystallization with a water-
soluble FS analog, 7-acetyl-7-[O-(N-methyl-piperazino)--butyryl)]-forskolin (MP-FS). Figure 
1 B shows a well-defined FS binding site in the cleft between C1 and C2. This pocket is 
structurally related to the active site that is on the opposite site of the catalytic cleft. Due to 
the fact that AC 9 has a different amino acid (AA) residue in this part of the binding site in 
comparison to ACs 1-8 (Y1082), it is not stimulated by FS, but FS-sensitivity can be restored 
by mutagenesis (Yan et al., 1998). The basic principle for the existence of the FS binding site 
is discussed in literature (Tesmer et al., 1997), but the search for a physiological FS analog 
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that might regulate ACs through this binding site was so far unsuccessful. One study 
detected a FS-like molecule in renal cysts of 15 patients suffering of polycystic kidney 
disease, but they could not clarify whether this molecule is physiologically relevant or might 
be derived from widely used dietary supplements that contain FS (Putnam et al., 2007). 
  
 A
  
 
Figure 1. Scheme of mAC and crystal structure of catalytic domains in complex with Gs.and FS. On the 
left side (A) the protein is depicted with the transmembrane domains M1 and M2 and the cytosolic domains C1 
and C2. The important interaction sites with physiological regulating G protein Gs (orange) and Gi (white) are 
also indicated. The right side (B) shows the first published crystal structure of the catalytic center of the protein 
(PDB 1AZS) (Tesmer et al., 1997). C1a and C2a are colored wheat and lightpink, respectively. They carry a 
water-soluble FS analog (MP-FS) in their catalytic cleft (C-atoms grey, N-atoms blue, O-atoms red). Gs  is 
colored orange and carries GTPS (C-atoms cyan, N-atoms blue, P-atoms orange, O-atoms red, S-atom yellow). 
Darkblue spheres are water molecules and one red sphere shows one Mg
2+
 ion, interacting with GTPS. The red 
arrow indicates the ATP binding site, responsible for catalysis. 
 
Binding of the P-site inhibitor 2‟-deoxy-3‟-adenosine monophosphate and pyrophosphate 
into Gs/MP-FS  stimulated VC1/IIC2 complex was used to identify the active site of mACs 
and the structural principles for catalysis as well as P-site inhibition (Tesmer et al., 1997; 
Dessauer et al., 1999). The substrate-binding site showed that divalent cations such as Mn2+, 
Ca2+ and Mg2+ bind into the catalytic site by a two metal ion mechanism. Mg2+ and Mn2+ 
stimulate ACs because they catalyze phosphoryl transfer in the active site, mainly by binding 
to the „B‟ metal site. It is speculated that Ca2+ tends to favor the „A‟ metal site thus leading to 
AC inhibition.  Besides the substrate-binding site there are numerous other interaction sites. 
At the opposite site of the catalytic site at the C2 domain is a cleft between 2‟ and 3‟ 
helices that interacts with Gs. It is still discussed how Gi interacts with the catalytic domains. 
Unfortunately no crystal structure of catalytic domains with Gi could be achieved until now, 
but mutagenesis studies indicated that a cleft in the C1 domain that is on the opposite site of 
A
  
B 
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the Gs binding site could be the interaction site (Dessauer et al., 1998) (Figure 1 A). 
Possibly, Gi stabilizes the open inactive conformation of the catalytic domains.  
It is quite interesting that C1 and C2 have relatively weak affinity for each other under 
basal conditions, but as soon as either FS or Gs are present, basal activity can be stimulated 
by more than 100-fold and affinity for these two domains is increased even more, when both 
proteins are present together (Whisnant et al., 1996). Unfortunately, it was not yet possible to 
crystallize mACs with only one of the two activators. But it may be possible that synergism of 
FS and Gs is initiated by a slight rotation of the two domains that binds ATP more tightly, 
therefore, increasing catalytic activity.  
  
The characterization of a more physiological homologous C1 and C2 crystal structure of 
mAC has not been achieved yet, mainly because of poor protein expression or due to 
instability of the expressed protein. There is also a crystal structure of the IIC2 homodimer 
available and this structure is very similar to the heterodimer except that it can bind two FS 
molecules (Zhang et al., 1997). Primary sequence and regulation of mammalian soluble AC 
is significantly different to transmembrane ACs, but sAC have the same overall structure and 
employ the same two-metal ion mechanism for catalysis, as identified with the sAC homolog 
CyaC (Steegborn et al., 2005). 
1.2. Heart function 
Many cellular mechanisms that are yet not totally elucidated are important for heart 
function. However, the focus will be on one main intracellular signal transduction in the 
myocardium, induced by the sympathetic nervous system (Figure 2). As soon as the body 
increases the oxygen demand due to psychological or physiological stress, the sympathetic 
nervous system is activated, the level of norepinephrine is increased and the contraction and 
cardiac output is elevated. On the cellular basis, norepinephrine is released from presynaptic 
vesicles after stimulation of sympathetic nerves and binds to membranous GPCRs, namely 
β1- and β2-adrenoceptors (β-AR) (Bristow et al., 1990). Although β1-ARs predominate over 
the other subtype in myocardium, β2-ARs appear to couple more efficiently to ACs. The 
importance of the third β-AR (β3-AR) in heart still remains to be elucidated (Lohse et al., 
2003). Agonists of β-AR turn on the GPCR pathway by activation of the stimulatory G protein 
that dissociates in Gs bound to GTP and Gβ. It has to be mentioned that β2-AR signaling 
can also inhibit AC via inhibitory Gi (El-Armouche et al., 2003; Förster et al., 2003). The Gs-
subunit couples to AC and increases the production of second messenger cAMP. This 
intracellular messenger then activates cAMP-dependent protein kinase (PKA) that increases 
intracellular Ca2+ levels via phosphorylation of L-type Ca2+ channels and thus contraction of 
myocytes takes place. Phosphorylation of Ca2+ channels increases open probability of the 
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channels detected by an increase in Ca2+ influx (ICa,L) from the extracellular space into the 
cytosol (Reuter, 1983). The increase in intracellular Ca2+ further activates Ca2+ release from 
the sarcoplasmatic reticulum (SR), thereby mediating the positive inotropic effect. Relaxation 
of cardiomyocytes is also achieved via cAMP-dependent phosphorylation of phospholamban 
(PLB), a Ca2+ transporter in the SR. Activation of phospholamban initiates the Ca2+ reuptake 
into the SR. Another cAMP-dependent mechanism that further aids in cardiomyocyte 
relaxation is the phosphorylation of troponin I, modulating myofilament Ca2+-sensitivity. 
 
 
Figure 2. “Classical” cardiac β-AR signaling. The common pathway activates AC via Gs, increasing cAMP 
levels. Via activation of protein kinase A (PKA), several proteins are phosphorylated that regulate the calcium 
homeostasis of the cell and thereby influencing cardiac contractile behavior. PKA phosphorylates not only L-type 
calcium channels (ICa,L), phospholamban (PLB) and troponin, but also ryanodine receptors, myosin binding 
protein and protein phosphatase inhibitors (not shown here) (Lohse et al., 2003). 
 
1.2.1. Voltage-dependent calcium channels 
Voltage-dependent Ca2+ channels (VDCC) are necessary for the function of nerve and 
muscle cells. Ca2+ channels are membranous heteromultimeric protein complexes that are 
selective for Ca2+ and regulate Ca2+ permeability by differences in membrane potential and 
Ca2+ gradient between the extracellular space and the cytosol. There are a variety of Ca2+ 
channels. The most important group consists of VDCC that are activated by depolarization of 
the cell membrane (Jones, 1998). According to their current properties, VDCC are 
subdivided into high voltage-activated and low voltage-activated channels (Ertel et al., 2000). 
A very important high voltage-activated Ca2+ channel is the L-type (long-lasting) Ca2+ channel 
that exhibits high conductance for Ca2+ and Ba2+ ions (Mikami et al., 1989). In heart, it 
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consists of four different subunits, a pore forming 1-domain, a modulating intracellular β-
domain, and a 2-domain, that couples the extracellular 2-subunit via transmembrane 
crossing -subunit to the pore forming domain. The membrane-traversing -subunit is not 
expressed in heart (Randall and Benham, 1999; Treinys and Jurevicius, 2008). The 1-
subunit is also functionally active when the other domains which stabilize and regulate the 
Ca2+ channel are not present. Regulation of the Ca2+ channel pore is mainly dependent on 
phosphorylation by PKA, but which phosphorylation site brings about activation could not be 
unequivocally established yet. C-terminal serine residues of the 1- and β2-subunit are 
thought to influence the activity of the whole channel (Dai et al., 2009). However, many other 
factors such as divalent cations and cytoplasmic factors affect channel activity (Yamaoka 
and Kameyama, 2003). Alterations in L-type Ca2+ channel function and expression play a 
role in the development of hypertrophy and heart failure (Beetz et al., 2009).  
1.3. Pharmacotherapy of chronic heart failure 
Cardiac insufficiency develops when the heart is unable to supply the organs with enough 
blood to maintain the oxygen demand of the organism. Patients suffer from a decreased 
exercise tolerance, dyspnea and fatigue, caused by changes in preload, afterload, heart 
contractility or heart rate. Mostly, the patients also complain about abdominal or leg swelling 
due to fluid retention. In Germany chronic heart failure is responsible for high health 
expenses, because it is one of the main reasons for hospitalization (Neumann et al., 2009). 
Cardiac insufficiency is a very serious and complex disease. Many pathophysiological 
mechanisms are responsible for the development of heart failure, such as myocardial 
hypertrophy, altered Ca2+ homeostasis and the activation of the sympathetic nervous system. 
The heart tries to compensate the decrease in oxygen supply by activation of the 
sympathetic nervous system, but this can be very harmful for the cardiovascular system. 
Patients suffering of cardiac insufficiency show very high plasma norepinephrine 
concentrations that correlate with the severity of the disease (Thomas and Marks, 1978; 
Cohn et al., 1984). Due to excessive catecholamine stimulation, the signal transduction is 
desensitized. If the receptor is constantly activated by β-AR agonists, phosphorylation of the 
receptor by β-adrenoceptor and cAMP-dependent protein kinases leads to internalization of 
the receptor, because β-arrestin binds to the phosphorylated receptor. This cytosolic protein 
initiates that the receptor is embedded in vesicles and removed from the cell membrane. 
Prolonged stimulation with catecholamines can lead to proteolysis of the receptor, so called 
down-regulation, together with a minimization of β-AR m-RNA (Engelhardt et al., 1996; 
Lohse et al., 1996). The positive inotropic effect of β-AR agonists is diminished due to down-
regulation at the receptor level, assessed by decreased isoprenalin effects. In conclusion, 
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decreased β-AR density, especially of β1-AR is experimentally demonstrated and is 
correlated with the severity of heart failure.  
A standard therapy for chronic heart failure is, therefore, the treatment with β-AR blockers 
that antagonize the effects of constant stimulation of the sympathetic nervous system, either 
by blocking detrimental β1-AR effects or by resensitizing the β-AR system (Lohse et al., 
2003). Especially cardioselective β1-blockers, such as metoprolol or bisoprolol, as well as the 
β- and 1-AR blocker carvedilol are useful drugs for the therapy of chronic heart failure. Many 
studies already demonstrated that β-blockers are the most important advance in heart failure 
therapy by decreasing severity of symptoms, increasing quality of life and reduction of 
mortality (Lechat et al., 1998; Lohse et al., 2003). 
Medication of heart insufficiency depends on the clinical stage of the disease. The 
“ACCF/AHA guidelines for the diagnosis and management of heart failure in adults” 
(American College of Cardiology Foundation/American Heart Association) assist 
cardiologists in clinical decision making (Jessup et al., 2009). In principle, chronic heart 
failure is subdivided into 4 clinical stages that determine the complex therapeutic approach. 
In addition to β-AR antagonists, angiotensin-converting enzyme inhibitors, angiotensin II 
receptor blockers, diuretics and digitalis are used as standard medication. Furthermore, the 
guidelines discuss additional medical approaches, such as vasodilators or aldosterone 
antagonists (Jessup et al., 2009). 
1.4. Adenylyl cyclase 5 in heart 
ACs play a major role in the development of heart failure because chronic activation of 
cAMP signaling, induced by overexpression of β-AR, Gs or PKA, results in cardiomyopathy 
(Iwase et al., 1997; Engelhardt et al., 1999; Antos et al., 2001). The heart expresses all AC 
isoforms, except AC 8 (Defer et al., 2000). AC 1 is only present in sino-atrial node. ACs 5 
and 6 are predominant and very closely related in terms of regulation (only PKC regulation 
quite different). At birth both isoforms are expressed equally and are most abundant in 
neonatal heart, but in adult heart AC 5 is dominant (Tobise et al., 1994). Due to preparation 
of a specific AC 5 mouse monoclonal antibody it could be detected that AC 5 is increased in 
heart with left ventricular hypertrophy in response to pathophysiological stress (Hu et al., 
2009). To understand the physiological role of both isoforms in heart and to identify if the 
isoforms couple to various signaling pathways, KO and overexpression studies were carried 
out (Okumura et al., 2003a; Tang et al., 2006; Tang et al., 2008).  
1.4.1. AC 5 knockout mice 
No compensatory increase in expression of other AC isoforms is detected in AC 5-/- mice. 
Especially the remaining AC 6 does not adopt the missing AC 5 activity. Basal AC activity is 
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decreased by  35%. Stimulated AC activity with isoproterenol, FS and GTPS was also 
diminished by 27-40%, indicating that AC 5 contributes to overall AC activity in a quite high 
amount, i.e.  30-40% (Okumura et al., 2003a). Interestingly, there was a total loss of 
carbachol-induced AC inhibition in comparison to WT mice. Carbachol is a muscarinic 
agonist that inhibits AC activity via Gi. Parasympathetic regulation seems to be mediated via 
AC 5 and could be the reason for an increased basal heart rate in AC 5-/- mice. No change in 
basal cardiac function was detected, but isoproterenol-stimulated left ventricular ejection 
fraction (LVEF) was significantly reduced. Electrophysiological measurements showed no 
differences in L-type Ca2+ current, but isoproterenol stimulation was significantly reduced and 
Ca2+ mediated inhibition was annihilated. Expression of G proteins and β-AR was not altered. 
Another KO model showed increased basal contraction of perfused hearts and decreased 
sensitivity to β1 agonists, but also a significant reduction of Gs expression (Tang et al., 2006). 
The influence of AC 5 gene deletion in the development of heart failure was of 
considerable interest. Pressure overload by aortic banding was used as heart failure model. 
The aorta thoracalis was constricted to generate an increased pressure in the left ventricle. 
In contrast to WT mice, left ventricular function was not altered in KO mice. AC 5-/- mice are 
protected against heart failure under stress conditions. Furthermore myocardial apoptosis is 
reduced in cardiomyocytes (Okumura et al., 2003b). Gene deletion of AC 5 protects against 
oxidative stress. The KO mice have an increased life span ( 30%) and age-induced cardiac 
myopathy is significantly reduced (Yan et al., 2007). However, it should be mentioned that 
beside of cardiac effects, AC 5 is also highly expressed in striatum and there it plays a role in 
the dopaminergic system. AC 5-/- mice develop Parkinson-like symptoms, such as abnormal 
coordination and bradykinesia that can be partially compensated by selective D1 and D2 
agonists that stimulate remaining AC isoforms (Iwamoto et al., 2003).  
 Studies on transgenic mice with deletion of AC 6 detected no change in basal AC activity. 
However, under stimulated conditions AC 5 is decreased via proteosomal degradation, 
leading to a reduced PKA activity and stimulated left ventricular contractile function (Tang et 
al., 2008).  
1.4.2. AC 5 overexpression 
An increased AC 5 expression in mice led to increased basal cAMP levels, elevated PKA 
activity and phospholamban phosphorylation. This increase in basal AC activity influences 
basal cardiac function, because heart rate is increased in transgenic mice. However, cardiac 
β-AR signaling is not altered, because β-AR agonists did neither influence L-type Ca2+ 
channel activity in isolated cardiomyocytes, nor was there any change in heart rate and 
contractility after agonist infusion (Tepe et al., 1999). Interestingly, AC 5 overexpression 
significantly improved β-AR dysfunction in a hypertrophic mouse model (Tepe and Liggett, 
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1999). Overexpression of Gq in cardiomyocytes resulted in hypertrophy and decreased 
cardiac contractility in vivo, due to a lack of basal as well as stimulated AC activity and an 
almost 50% decrease in AC 5 expression. As soon as AC 5 expression is restored in mice 
that overexpress Gq and AC 5, dysfunction of β-AR signaling and cardiac contractility are 
compensated. The same happened when AC 6 was overexpressed with Gq (Roth et al., 
1999). AC 6 overexpression in mice did not influence basal heart rate and contraction, but 
increased cardiac response to β-adrenergic stimulation (Gao et al., 1999). 
 
 In order to summarize all the studies that were performed to characterize ACs 5 and 6 in 
heart, it has to be stated that production and utility of cAMP is clearly not one simple 
mechanism: under stress conditions cAMP might be harmful (as illustrated in the AC 5-/-
model), but it can be quite beneficial when other factors are altered (overexpression of ACs 5 
or 6 in Gq transgenic mice). Overexpression or gene deletion of AC 6 did not provoke any 
pathophysiological changes. In contrast, AC 6 is often stated to be beneficial in heart failure 
therapy (Phan et al., 2007).    
1.5. AC inhibition 
AC regulation via stimulation with AC activators or inhibition with antagonists could have 
many pharmacotherapeutic applications. Especially, the tissue-specific distribution of some 
isoforms, to mention ACs 1, 5, 7 and sAC, may be used to develop drugs against 
Alzheimer‟s disease, heart failure, alcoholism, drug abuse and male fertility (Pierre et al., 
2009).  
Inhibitors of AC 5 may be useful drugs for the therapy of heart failure and could increase 
longevity (Chester and Watts, 2007; Okumura et al., 2009). Inhibition of AC 1 via specific 
AC 1 inhibitors could be used for neuroprotection. Deletion of AC 1 in mice significantly 
attenuated neuronal death induced by glutamate in primary cultures of cortical neurons 
(Wang et al., 2007). Prevention of excitotoxicity via inhibition of AC 1 could be used for the 
treatment of stroke and neurodegenerative diseases (Watts, 2007). 
1.5.1. MANT nucleotides 
 This group of potent AC inhibitors are nucleotides that possess a small fluorophore, N-
methylanthraniloyl (MANT), bound to the 2‟ or 3‟ O-ribosyl group of the nucleotides (Jameson 
and Eccleston, 1997). Therefore, they can be used in fluorescence studies to detect enzyme 
kinetics. Various MANT nucleotides are available as fluorescent probes. Figure 3 shows the 
structure of the MANT nucleotides and gives an overview about structural changes that were 
applied to improve stability. The fluorophore possesses an additional advantage; it increases 
the lipophilicity, and thus could facilitate the passage through the cell membrane. 
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Figure 3. Structure of MANT nucleoside 5’-triphosphates (NTPs) and MANT nucleoside 5’--thio-tri-
phosphate (NTPS). Represented are the MANT nucleotides used for crystallography and patch-clamp 
experiments, MANT-ITP, MANT-GTP, MANT-ITPS, MANT-GTPS and MANT-ATP. The MANT-group 
isomerizes between the 2‟ and 3‟-O-ribosyl function. 
 
The following data suggest that MANT nucleotides are very potent AC inhibitors and that 
they express their inhibitory effect by competition for the ATP-binding site using Lineweaver-
Burk analysis (Gille and Seifert, 2003b; Gille et al., 2004). 
In the search for a test system to study kinetic interaction of receptor/G protein coupling, 
these fluorescent nucleotides were examined to establish a fluorescent high-throughput 
screening method. Until now, most studies are performed with radiolabeled nucleotides, such 
as 35SGTPS, α-32PGTP azidoanilide or -32PGTP (Gierschik et al., 1994; Laugwitz et al., 
1994). MANT-GTPS and MANT-GppNHp were already tested on purified G proteins and 
showed relatively high affinity and changes in fluorescence upon G protein binding 
(Remmers and Neubig, 1996; Remmers, 1998). Gille and Seifert tested MANT-GTPS and 
MANT-GppNHP for their affinity to recombinant Gs/Gi fusion proteins, expressed in a 1:1 
ratio with the formyl peptide receptor or the β2-adrenergic receptor (Gille and Seifert, 2003a). 
MANT-GTPS had a 30- to 300-fold lower affinity to Gs/Gi fusion proteins compared to 
GTPS. The Ki values of both MANT nucleotides for the different G fusion proteins were 
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250 – 1,120 nM for MANT-GTPS and 1,200 – 5,700 nM for MANT-GppNHp, indicating that 
MANT nucleotides can bind and also inhibit G proteins, but very surprisingly with much lower 
affinity than mACs (Gille and Seifert, 2003b; Gille and Seifert, 2003a).  
To ensure that MANT-GTPS inhibits GTPS-stimulated AC in the Gs-membrane 
preparation, AC activity assays on Gs-deficient S49cyc
- lymphoma cell membranes were 
conducted (Gille and Seifert, 2003b). This Gi-model system showed AC inhibition under 
Mg2+ conditions when GTPS or GppNHp were applied. But under Mn2+ conditions Gi is 
blocked and GTPS or GppNHp cannot activate the G protein. Nevertheless, MANT-GTPS 
and MANT-GppNHp still showed an inhibitory effect on AC activity under Mn2+ conditions, 
with Ki values of 53 nM and 160 nM, respectively. The production of cAMP was reduced by 
direct inhibition of AC and not via Gi. 
1.5.1.1. AC inhibition by MANT nucleotides 
During the last years, many other MANT nucleotides were tested for their inhibitory 
potency on mACs.  
 
Table 2. Inhibition of mAC activity/catalytic activity by MANT nucleotides. AC activity assays were 
conducted with 5 mM MnCl2 or MgCl2 and 100 µM FS. The catalytic activity of VC1/IIC2 was measured with 10 
mM divalent cation and 100 µM FS. Ki values were calculated using obtained IC50 and Km values (Cheng-Prusoff 
equation). Standard deviations (SD) were generally smaller than 20% of the means. Mean values ± SD are 
integrated using 4-5 independent duplicate experiments of at least 2 different membrane preparations or protein 
batches. Values taken from (Göttle et al., 2009) are labeled with (*) and from (Gille et al., 2004) are labeled with 
(
+
). The other values are taken from (Geduhn, 2009). Abbreviation: n.d. = not done  
MANT 
nucleotide 
AC 1 AC 2 AC 5 AC 6 Cardiac 
AC 
VC1/IIC2 + FS 
+ Gs-GTPS 
MANT-ITP 
3* 
24* 
14* 
65* 
1* 
13* 
3* 
n.d. 
4* 
24* 
0.7 ± 0.1 
n.d. 
MANT-GTP 
90
+
 
1,500* 
620
+
 
3,700* 
55
+
 
760* 
91
+
 
n.d. 
21* 
780* 
18 ± 6 
n.d. 
MANT-ITPS 
41
+
 
300* 
120
+
 
450* 
31
+
 
150* 
43
+
 
n.d. 
8* 
26* 
19 ± 3.3 
n.d. 
MANT-GTPS 
62
+
 
990* 
360
+
 
1,800* 
35
+
 
550* 
48
+
 
n.d. 
23* 
340* 
24 ± 4.1 
n.d. 
MANT-ATP 
210
+
 
3,200* 
850
+
 
5,700* 
200
+
 
2,000* 
280
+
 
n.d. 
64* 
2,000* 
16 ± 6.4 
n.d. 
MANT-ATPS 
160* 
1,400* 
380* 
2,300* 
77* 
1,100* 
72* 
n.d. 
67* 
770* 
n.d. 
n.d. 
MANT-XTP 
1,100 ± 100 
n.d. 
3,000 ± 200 
n.d. 
1,300 ± 400 
n.d. 
n.d. 
n.d. 
1,300 ± 400 
n.d. 
1,200 ± 370 
n.d. 
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Table 2 gives an overview about the Ki values (in nM) of different MANT nucleotides under 
Mn2+ and Mg2+ conditions on recombinant ACs 1, 2, 5 and 6 in Sf9 insect cell membrane 
preparations, on catalytic domains C1/C2 and on cardiac AC membrane preparations. 
MANT-ITP turned out to be the most potent AC 1/5 inhibitor known so far (Ki  1-3 nM) and it 
also had the highest inhibitory effect on purified catalytic AC subunits C1/C2 (Ki  0.7 nM). 
Furthermore, MANT nucleotides inhibit ACs 1 and 5 with a much higher potency than AC 2, 
and this is explained by differences in the binding pocket that change affinity, because two 
amino acid residues are different. Therefore, it is possible that changes in the MANT 
nucleotide structure, for instance in the MANT-group, may influence the selectivity profile of 
these substances for a specific AC isoform.  
1.5.1.2. MANT nucleotides as fluorescent probes 
Due to the fact that MANT nucleotides are fluorescent, we have a good tool in hand to 
study the kinetics of AC/nucleotide interaction. With the help of the purified catalytic subunits 
VC1 and IIC2 we could study the molecular interactions of MANT nucleotides with the protein 
via fluorescence analysis. MANT nucleotides interact directly with the two protein domains 
thereby changing fluorescence properties (Figure 4). MANT nucleotides show a direct 
emission peak at  450 nm, when excited at 350 nm (blue line). This fluorescence is 
increased when the MANT-group of the nucleotide gets into a more hydrophobic 
environment and the emission peak shows a “blue-shift” to  420 nm. Furthermore the 
nucleotide can trigger a fluorescence resonance energy transfer (FRET) from W1020 of IIC2 
to the MANT-group, as soon as the nucleotide comes into closer distance to the binding site 
(Mou et al., 2006). The dashed black lines in Figure 4 show endogenous fluorescence of 
C1/C2 tryptophan and tyrosine residues excited at 280 nm, when no MANT nucleotide is 
present. As soon as C1 and C2 are mixed with MANT nucleotide a FRET at  420 nm in the 
emission spectra (em = 300 - 500 nm) is detected, that increases by addition of FS, because 
FS promotes C1/C2 assembly. Several MANT nucleotides were tested using fluorescence 
spectroscopy, but only MANT-ITP showed a very strong increase of basal FRET and direct 
fluorescence after addition of C1 and C2 and without FS (Figure 4 C and D). The application 
of FS afterwards had only minor effects on FRET and direct fluorescence. It seems that 
MANT-ITP already promoted the catalytic subunit assembly without the presence of FS. 
Compared to MANT-ITP, MANT-GTP showed a smaller effect on basal FRET and direct 
fluorescence (Figure 4 A and D). In contrast, MANT-XTP had almost no influence on FRET 
and direct fluorescence (Figure 4 E and F). 
 
Finally, it is important to mention, that MANT nucleotides are racemates, so the tested 
nucleotides are a mixture of two isomers. For comparison of the potency of pure isomers, we 
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need the pure 2‟- or 3‟-deoxy compounds, but until now only some are commercially 
available, and the synthesis is very difficult. 
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Figure 4. Fluorescence 
emission spectra of MANT-
GTP (A/B), MANT-ITP (C/D) and 
MANT-XTP (E/F). 
Emission at ex = 280 nm (em = 
300 - 500 nm) and at ex = 
350 nm (em = 370 - 500 nm) are 
represented. Experiments were 
conducted at 25°C in the 
presence of MANT nucleotides 
(1 µM), VC1 (5 µM) and IIC2 
(25 µM) without and with FS 
(100 µM). Reactions mixtures 
contained a buffer of 100 mM 
KCl, 10 mM MnCl2 and 25 mM 
HEPES/NaOH, pH 7.4. Three 
independent experiments with at 
least two different batches of 
VC1/IIC2 were performed. 
Measurements were accomp-
lished by Cibele Pinto and 
Roland Seifert while working at 
the University of Kansas, 
Lawrence, KS. Fluorescence 
intensities are shown in %. 
 
 
 
 
Legend:
Nucleotide + C1/C2
Nucleotide + C1/C2 + FS
C1/C2 only
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1.5.2. Other AC inhibitors 
The classical AC inhibitors are P-site inhibitors, adenosine analogs that bind to the ATP 
binding site and block pyrophosphate release (Johnson et al., 1989; Desaubry et al., 1996). 
Therefore they inhibit AC only in the presence of pyrophosphate. The most potent P-site 
inhibitors consist of 3‟-mono- or polyphosphates and 2‟,5‟-dideoxyribose moieties. P-site 
inhibitors tested on purified AC from bovine and rat brain showed quite high potency in the 
nM range (IC50  10 nM) and no effect on other effector proteins of the cAMP signal cascade, 
such as PKA and phosphodiesterase (Desaubry and Johnson, 1998). However, there is one 
drawback; these substances are not very isoform-specific (Johnson et al., 1997). Another 
class of compounds that also belongs to the group of P-site inhibitors, including 1R,4R-3-(6-
aminopurin-9-yl)-cyclopentane-carboxylic acid hydroxyamide, selectively inhibited AC 5 in 
comparison to AC 2 and 3, but the IC50 values were in the µM range. The above-mentioned 
compound showed a reduction of myocardial apoptosis under excessive β-AR stimulation 
with isoprenalin (Iwatsubo et al., 2004). 
One group of competitive inhibitors are dideoxy nucleotides, such as β-L-2‟,3‟-dideoxy 
adenosine 5‟-triphosphate, but nothing is published about their isoform-selectivity (Shoshani 
et al., 1999). Therefore, MANT nucleotides are a good starting point for the development of 
pharmacotherapeutics, because they show a competitive enzyme inhibition, a high potency 
and partial isoform-selectivity (Gille et al., 2004; Mou et al., 2005). 
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1.6. Aims of the project 
1.6.1. Purification of C1/C2 and crystallization 
MANT nucleotides are potent inhibitors of mACs that bind to the catalytic center of the 
enzyme and exhibit Ki values in the nanomolar range. We were particularly interested to 
understand the molecular mode of AC inhibition by different MANT nucleotides. Previous 
studies showed that the catalytic site of AC is quite flexible and binds a diverse range of 
nucleotides (Mou et al., 2006; Suryanarayana et al., 2009). The catalytic site of C1/C2 can 
accommodate large chemical alterations of nucleotide inhibitors. Furthermore, the MANT 
nucleotides differ from each other in their fluorescence properties. Large differences in direct 
fluorescence and FRET were detected when the MANT nucleotides were mixed with C1/C2 
and stimulated by FS. These data indicate that MANT nucleotides can have different 
localization in the catalytic site of the protein and that there are alternate binding modes 
possible. MANT-ITP is the most potent mAC inhibitor known so far (Göttle et al., 2009).   
 
However, the reason for this high affinity binding on molecular basis is still unknown. The 
first aim of this study was to elucidate the structural basis for the interaction of MANT-ITP 
with mAC. In order to achieve this aim, X-ray crystallography was used. The catalytic 
domains C1a and C2a of mAC were purified and activated by Gs-GTPS and FS. The 
crystal structure of this complex, bound to MANT-ITP:Mn2+, was determined and compared 
to the published crystal structure of mAC with  MANT-GTP. Both nucleotides consist of a 
purine base and have very similar structures. MANT-ITP just misses an NH2 group at C2 of 
the guanine ring. Until now it was expected that the base substitution has relative little impact 
on nucleotide-affinity, because purine as well as pyrimidine bases are well tolerated and 
show high affinity (Mou et al., 2006). However, the deletion of the NH2 group increased 
potency of MANT-ITP for mACs by up to 50-fold compared to MANT-GTP and furthermore 
C1/C2 assembly assessed by fluorescence spectroscopy was quite different for both ligands. 
Therefore, we wished to understand the binding mode of MANT-ITP in more detail and to 
identify the role of the different nucleotide substituents (base, phosphate chain, MANT-group) 
for nucleotide affinity. Possibly, the base plays a much more important role on overall binding 
affinity as what was expected before.  
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1.6.2. Effect of MANT nucleotides in intact cells  
 ACs play a major role in the GPCR signal transduction and due to their specific tissue 
distribution they could be used as pharmacological targets in the development of 
therapeutics for various diseases. Due to the fact that chronic heart failure is a common and 
serious disease and inhibition of AC 5 seems to be cardioprotective, as assessed by AC 5-/- 
mice and inhibition of myocardial apoptosis with P-site inhibitors, development of selective 
AC 5 inhibitors is a good starting point for future heart failure therapy (Okumura et al., 2003b; 
Iwatsubo et al., 2004). Inhibitors of AC 5 could reduce apoptotic processes in patients 
suffering of cardiac insufficiency. With the discovery of MANT nucleotides that are potent and 
competitive AC inhibitors, we have a good basis for further development of isoform-specific 
drugs. However, all these compounds have so far only been tested in membrane 
preparations that recombinantly express a specific AC isoform or they were tested in tissue 
membrane preparations (Gille et al., 2004; Göttle et al., 2009). As read-out, AC activity was 
assessed, but not yet the functional consequences of AC inhibition.   
  
 Therefore, we studied the effects of MANT nucleotides in intact murine cardiomyocytes. 
Due to the fact that the signal cascade in cardiomyocytes is predominantly influenced by 
mAC activity, measurement of L-type Ca2+ channel activity can be used to study the effects 
of mAC inhibitors. One MANT nucleotide, MANT-GTPS, already showed inhibition of basal 
and isoprenaline-stimulated voltage-dependent Ca2+ channels in ventricular cardiomyocytes 
of WT mice, indicating that ACs play a major role in cardiac signaling. The inhibitory effect 
was attenuated when cardiomyocytes of AC 5-/- mice were treated with MANT-GTPS, 
indicating that this AC inhibitor mainly influences L-type Ca2+ currents via AC 5 inhibition 
(Rottländer et al., 2007).  
  
 The aim of our current study was to assess if other MANT nucleotides, specifically MANT-
ITP, exhibit a larger pharmacological effect in intact cells. Additionally, we used as “negative 
control” a MANT nucleotide that inhibits AC only with modest potency, MANT-ATP. MANT-
GTPS can also inhibit G proteins with low affinity (Gille and Seifert, 2003a). Therefore, the 
second aim of our study was to examine the effects of NTPs with higher selectivity for AC 
relative to G proteins, MANT-ITP and MANT-ATP. 
 Furthermore, we wanted to assess the stability of the MANT nucleotides in intact cells. 
Until now, the inhibitory potencies of MANT nucleotides were tested in membrane 
preparations, using a regenerating system to stabilize the tested nucleotides against 
enzymatic degradation. We examined the effect of the hydrolysis-sensitive phosphate group 
relative to the hydrolysis-resistant phosphorothioate group in MANT-NTP versus MANT-
NTPS on Ca2+ channel regulation by the application of MANT-GTPS and MANT-ITPS. 
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The structure of MANT nucleotides does not allow good absorption of the substances 
through the cell membrane. Therefore, we used the whole cell patch clamp technique to 
apply the MANT nucleotides directly into the cell through the pipette solution.  
 
Within this work we wanted to clarify the following questions: 
1. Do we see differences in L-type Ca2+ current inhibition in correlation to their AC 5 
inhibitory effect?  
2. How stable are MANT-NTPs that are not protected from degradation by phosphatases 
in comparison to MANT-NTPS? 
3. What is the incubation time for the MANT nucleotides until they express an inhibitory 
effect on L-type Ca2+ current after administration of the substances through the pipette? 
 
Materials and Methods 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Equipment 
Analytical balance          BP211D, Sartorius, Göttingen 
                SBC21, Scaltec Instruments, Göttingen 
Autoclave (steam sterilizer)       Varioklav 135 S, Thermo Scientific, Erlangen 
Cell lysis             Multiquick handblender, 300 Watt, Braun 
Centrifuge             Multifuge 3 L-R, Heraeus, Hanau 
                Super T-21, Sorvall, Thermo Scientific 
Heating plate and stirrer        IKAMAG RCT basic, IKA Werke, Staufen 
                MR3001, Heidolph Instruments,Schwabach 
Incubator shaker           Innova 43, New Brunswick Scientific 
Myocyte isolation: 
 Heated circulating bath        F423, Haake, Berlin 
 Langendorff-setup         University of Cologne, custom-made 
Patch-clamp setup: 
Analog-Digital converter  Digidata 1440A, Axon Instruments, 
Moleculare Devices, Sunnyvale, CA, USA 
 Battery             Solarpower; energy supply for microscope  
 Faraday cage           University of Cologne, custom-made 
 Main amplifier           Axopatch 200A and B, Axon Instruments 
 Microelectrode amplifier (preamplifier)   CV 201 AU and 203 BU headstage, Axon 
 Inverse microscope         Nikon Diaphot, Nikon Instruments Europe  
 Micromanipulator         MO-102/ MHW-103, Narishige, London, UK 
pH-meter             Orion EA940, Thermo Fisher Scientific  
                pH526, WTW, Weilheim 
Pipette puller            P97 pipette puller, Sutter Instruments, USA 
Power supply for SDS-PAGE/Western Blot  Power Pac Basic Power Supply, Bio-Rad 
Protein purification          Äkta FPLC, GE Healthcare, Freiburg 
                BioLogic DuoFlow Systems, Bio-Rad 
 Ion-exchange columns        Mono S 5/50 GL, GE Healthcare 
                HiTrap Q FF 1 ml, GE Healthcare 
                Q Sepharose FF, GE Healthcare 
 Hydroxyapatite column (HAP-column)  CHT Ceramic Hydroxyapatite Type I    
                resin, Bio-Rad 
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 Affinity columns          HisTrap FF 5 ml, GE Healthcare    
                Profinity IMAC Ni-charged resin, Bio-Rad 
                Talon Superflow resin, BD Biosciences 
 Size exclusion columns       Superdex 75 10/300, GE Healthcare 
                Superdex 200 10/300, GE Healthcare 
 Sample loading          Superloop 50/150 ml, GE Healthcare 
 Empty columns          XK columns (e.g. 26/20), GE Healthcare  
                University of Regensburg, custom-made 
                Glass Econo-column, Bio-Rad 
Shaking water bath          Julabo SW-20C, Julabo, Seelbach  
Sterilizing oven           Heraeus, Hanau 
Ultra centrifuge (rotor and equipment)    TGA 45 (TFT4594), Kontron Instruments 
Vertical electrophoresis system      Mini-PROTEAN Tetra Cell, Bio-Rad, München 
Western Blot            Mini Trans-Blot Cell, Bio-Rad 
X-ray film processor          Cawomat 2000 IR, CAWO, Schrobenhausen 
2.1.2. Chemicals/enzymes 
Acrylamide 30% (m/v)  acrylamide/bis-acrylamide     Sigma-Aldrich, Taufkirchen 
Antibiotics      Ampicillin sodium salt      USB, Cleveland, Ohio, USA 
Kanamycin monosulfate     Sigma-Aldrich  
Antibodies      primary:  6xHIS (mouse)    Clontech, Mountain View,  
         0.5 mg/ml IgG2a (1:5000 dilution)  CA, USA 
         secondary: HRP anti-mouse (goat) Santa-Cruz Biotechnology, 
         0.4 mg/ml IgG (1:1000 dilution)   Heidelberg       
-ME        -mercaptoethanol       Sigma-Aldrich 
BSA        bovine serum albumin      Sigma-Aldrich 
Coomassie blue    brilliant blue R 250       Sigma-Aldrich 
CaCl2  2H2O     calcium chloride dihydrate    Merck, Darmstadt 
Collagenase      type 1 and 2, Worthington     CellSystems, St. Katharinen 
CsCl        caesium chloride        Roth, Karlsruhe 
CsOH       caesium hydroxide       Sigma-Aldrich 
Detection Reagent 1/2  Peroxide and Enhancer solution  Thermo Scientific , Erlangen 
DMSO       dimethyl sulfoxide       Sigma-Aldrich 
DNase I       desoxyribonuclease, bovine    Sigma-Aldrich 
DNA-Marker     Gene Ruler 1kb DNA-Ladder   Fermentas, St. Leon-Rot 
DTT        dithiothreitol         Sigma-Aldrich/GERBU 
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EDTA/ EGTA     ethylenediaminetetraacetic acid/   Sigma-Aldrich 
         ethylene glycol-bis (2-aminoethylether)-N,N,N‟,N‟-tetraacetic acid 
Glucose       D(+)-glucose         Merck 
Glycerol       87% (v/v) solution       Applichem, Darmstadt 
Glycine                    Merck 
HCl        hydrochloric acid        Merck 
HEPES       4-(2-hydroxyethyl)-1-piperazine-  Sigma-Aldrich 
         ethanesulfonic acid       USB, USA 
Heparin       Liquemin® 5000 I.E./ml      Roche, Grenzach-Whylen 
Imidazole      1,3-diazacyclopenta-2,4-diene   Sigma-Aldrich/Fluka  
IPTG        Isopropyl β-D-thiogalactopyranoside Fisher Scientific, Schwerte 
KCl        potassium chloride       Roth 
KH2PO4       potassium phosphate monobasic  Merck 
K2HPO4       potassium phosphate dibasic   Sigma-Aldrich 
Leupeptin      N-acetyl-L-leucyl-L-leucyl-L-argininal GERBU, Gaiberg 
MANT-ATP     MANT-adenosine 5‟-triphosphate  Jena Bioscience, Jena 
MANT-GTPS     MANT-guanosine 5‟--thiotriphosphate  
MANT-ITP      MANT-inosine-triphosphate    gift of Dr. J. Geduhn, UR 
MANT-ITPS     MANT-inosine 5‟--thiotriphosphate  Jena Bioscience 
MgCl2  6H2O     magnesium chloride hexahydrate  Merck, Sigma-Aldrich 
MgSO4  7H2O    magnesium sulfate heptahydrate  Merck 
Mg-ATP       adenosine-5‟-triphosphate, Mg salt  Sigma-Aldrich 
NaCl        sodium chloride        Merck, Sigma-Aldrich, Roth 
NaH2PO4  1H2O    sodium dihydrogen phosphate    Merck 
NaOH       sodium hydroxide       Merck 
NH4SO4       ammonium sulphate      Merck 
PEG 400/8000    polyethylene glycol       Merck 
PMSF       phenylmethanesulfonyl fluoride   Roche/Sigma-Aldrich 
Ponceau S      Acid Red 112, diazo dye     Sigma-Aldrich 
Protein Standard    Precision Plus Dual Color     Bio-Rad, München 
         Page Ruler #SM0669      Fermentas 
SDS        sodium dodecyl sulfate      Merck 
TLCK       N-tosyl-L-lysine chloromethyl ketone AppliChem/Sigma-Aldrich 
TPCK       tosyl phenylalanine chloromethyl ketone  
Tris        tris(hydroxymethyl)aminomethane  Roth, Invitrogen 
Trypsin inhibitor    Type II-L, Lima Bean      Sigma-Aldrich 
Tween 20      Polysorbat 20         Merck 
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2.1.3. Consumables 
Borosilicate capillaries   pipette manufacturing       Hilgenberg  
Centrifugal filter devices  Centriprep YM-10, MWCO 10 kDa   Millipore  
          Microcon YM-10, MWCO 10 kDa   Millipore  
          Jumbosep 10K, MWCO 10 kDa    Pall Life Sciences USA  
          Vivaspin MWCO 3, 10, 30 kDa     Sartorius Biotech   
Cheesecloth      250 µm, nylon          Reichelt, Heidelberg 
Cryo loop       Crystal Cap Copper Magnetic    Hampton Research 
          Adjustable Mounted CryoLoop    Hampton Research 
Crystallization trays    Cryschem 24 well plates      Hampton Research 
          VDX 24 well plates        Hampton Research 
Glass cover slides    circle and square forms (22 mm)   Hampton Research 
Insulin syringe     1 ml, sterile           Becton Dickinson 
Infusion set      Intrafix® air           B. Braun 
Injection needles     21G, 22G, 27G BD Microlance    Becton Dickinson 
Nitrocellulose membrane  0.45 µm Trans-Blot® Transfer medium Bio-Rad     
Mess dishes      35 x 10 mm Petri dish       Falcon 
Photo film       Amersham Hyperfilm ECL     GE Healthcare 
Pipette tips       10 µl, 200 µl, 1000 µl       Sarstedt 
Test tubes       1.5 and 2 ml micro tubes      Sarstedt      
          15 and 50 ml Falcon tubes     Sarstedt 
Serological pipettes    1 ml, 5 ml, 10 ml, 25 ml, steril    Sarstedt  
Single-use syringe    2 ml, 5 ml, 10 ml, 20 ml steril     B. Braun 
Sterile filters      Filtropur S 0.2 µm        Sarstedt 
          Sterifix 0.22 µm          B. Braun 
Transfer pipette      disposable, 2 ml         Sarstedt  
Vacuum grease     Dow Corning® vacuum grease    Hampton Research 
2.1.4. Computer software 
CCP4 program suite          Collaborative Computational Project No. 4, UK 
Coot              Crystallographic Object-Oriented Toolkit, UK 
Excel, PowerPoint, Word       Microsoft Office 2003, 2007 
Endnote             Version X and X3, Thomson Reuters 
Gene Runner           Version 3.01, Hastings Software 
GraphPad Prism          Prism 5.0, GraphPad, USA 
pClamp             pClamp6 and Clampex 10.2, Axon Instruments 
PyMOL             DeLano Scientific, USA – now Schrödinger 
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2.2. Methods 
2.2.1. Purification of mAC subunits C1/C2 and Gs 
This chapter describes the procedure for protein purification of the following proteins (Hatley 
et al., 2002): 
 
VC1       catalytic subunit C1a of canine AC 5 
IIC2       catalytic subunit C2a of rat AC 2 
Gs       -subunit of bovine stimulatory G protein  
2.2.1.1. Plasmids 
Plasmids used for the expression of the aforementioned proteins were a kind gift from Steve 
Sprang (PhD) and Tung-Chung Mou (PhD), University of Montana (UMT).  
  
2.2.1.2. Bacteria 
The following table shows the bacteria used for protein expression and plasmid amplification: 
 
Bacteria Application Reference 
Escherichia coli BL21-DE3, 
containing pREP4 plasmid 
protein expression of VC1 and IIC2 
gift of Drs. Steve Sprang 
and Tung-Chung Mou, UMT 
Escherichia coli JM109 protein expression of Gs 
gift of Drs. Steve Sprang 
and Tung-Chung Mou, UMT 
Escherichia coli TOP10 plasmid amplification 
One Shot
® 
TOP10, 
Invitrogen 
Plasmid Characteristics Application Antibiotic 
resistance 
pQE60-H6-VC1 
(364-580) 
4071 bp 
Restriction site Nco I - Hind III 
protein expression of N-terminal HIS-
tagged C1a of canine AC 5 (216 AA) 
Ampicillin
 
pQE60-ArgC-
IIC2 
4030 bp 
Restriction site EcoR I - Hind III 
protein expression of tag-less C2a of 
rat AC 2 (207 AA) 
Ampicillin
 
pREP4 [M15] low-copy plasmid 
3740 bp  
Qiagen Cat. # 342010 
expresses lac repressor protein, 
regulator of protein expression in  
Escherichia coli BL21  
Kanamycin 
pQE60-Gs-H6  protein expression of C-terminal HIS-
tagged bovine Gs  
Ampicillin 
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2.2.1.3. Preparation of heat shock competent cells  
 E.coli cells were plated on culture plates without antibiotics and incubated overnight. The 
next day, 10 ml LB media was inoculated and incubated overnight. Part of this stock was 
used to inoculate SOB media in a dilution 1:100. As soon as the optical density at 600 nm 
(OD600) of 0.5 to 0.7 was reached, the suspension was placed in ice cold water for 15 min to 
stop bacterial growth. The media was replaced by centrifugation at 2,500 rpm at 4°C and the 
pellet was treated with RF1 buffer for 1 h on ice. The buffer was replaced by RF2 buffer and 
the cell suspension was divided into 100 µl aliquots, frozen in liquid N2 and stored at -80°C. 
 
 RF1 buffer           pH 5.8         RF2 buffer     pH 6.8 
 K+-acetate    35 mM          MOPS      10 mM 
 CaCl2     10 mM         CaCl2      75 mM  
 MnCl2     50 mM         RbCl       10 mM 
   RbCl          100 mM         Glycerol          15% (v/v) 
 Glycerol        15% (v/v)   
  
Buffers were sterile-filtered and pH-adjustment was done with 0.2 M acetic acid.    
  
2.2.1.4. Transformation of E.coli 
 All the time we used freshly transformed E. coli, even though bacteria can be used for 
4 weeks when stored at 4°C.  
 Competent E.coli cells were gently thawed in a warm hand and placed on ice for 10 min. 
After addition of 2-10 ng plasmid, cells were incubated for 30 min on ice. The cells were 
heated for 1 min at 42°C and immediately placed on ice for 3 min. After adding 900 µl LB or 
SOC medium the cells were incubated for 1 h without antibiotics at 37°C and 150 rpm. A 
small aliquot (ca. 100 µl) of the cell suspension is then plated on a selective culture plate 
(2.2.1.6) and incubated overnight at 37°C. A separate part of the overnight culture (700 µl) 
was frozen and stored at -80°C after addition of 300 µl 50% (v/v) glycerol.  
2.2.1.5. Restriction digestion and sequencing 
 Restriction digestion was used to identify the quality of amplified DNA. Restriction 
endonucleases are enzymes, expressed by bacteria that can recognize and cleave specific 
base sequences in double stranded DNA. Enzymes and buffers used for analysis of our 
amplified DNA were purchased from NEB (New England Biolabs). For analytic detection of 
DNA fragments 0.1-0.5 µg DNA was digested with 1 µl restriction enzyme ( 3-5 U) at a 
specific temperature in a 15 µl batch. After 2 h in a heating block, the digestion was 
terminated and the reaction was further evaluated by gel electrophoresis.  
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 Another evaluation was performed by sequencing a specific DNA sequence of our 
amplified DNA to determine and assess the correctness of the nucleotide sequence. 
Sequence analysis of the Department of Pharmacology was carried out by Entelechon 
(Regensburg).  
2.2.1.6. Culture media 
 Plasmid amplification was performed using the standard LB medium. Protein expression 
was achieved using special T7 medium. Media were autoclaved for 20 min at 121°C, 1 bar. 
Temperature-sensitive substances, e.g. antibiotics, were added to the media shortly before 
inoculation with bacteria or for the preparation of culture plates at around 50°C.  
 
LB media, pH 7.41:                T7 media, pH 7.2 
Trypton             10.0 g          Trypton               20.0 g 
Yeast exract           5.0 g          Yeast extract           10.0 g 
NaCl              10.0 g          NaCl               5.0 g 
H2Odest                       ad 1.0 L          Glycerol                               2 ml 
                  KHPO4 (pH 7.2)      200 mM 
1culture plates: addition of 15 g Agar        H2O              ad 1.0 L 
 
Antibiotics were added with the following concentrations, depending on the bacteria used: 
Antibiotic Stock TOP 10 BL21-pREP4 JM109 
Ampicillin (Amp) 100 mg/ml in EtOH (50% v/v) 100 µg/ml 50 µg/ml 100 µg/ml 
Kanamycin (Kan) 50 mg/ml in H2Obidest - 50 µg/ml - 
 
 For protein expression the plasmids were transformed into BL21-pREP4/JM109 cells and 
plated on LB Amp/Kan or Amp culture plates. The next day 100 ml LB media were inoculated 
by picking single colonies from the culture plate. The suspension was incubated overnight at 
37°C and at 200 - 250 rpm in an incubator shaker. The next day, the overnight culture stock 
was centrifuged at 3,000 rpm and the pellet was used for inoculation of T7 expression media.  
2.2.1.7. Expression and cell lysis of C1/C2 and Gs  
Due to the fact that the expression level varied between the 3 different proteins, we used 
different expression protocols.  
 
VC1 protein expression 
 VC1 is only expressed in very small amounts ( 3 mg/12 L) and due to the fact that the 
protein is very unstable, expression was initiated at low temperature and for a short period. 
Materials and Methods 
 27 
Therefore, we inoculated 12 L T7 media with the overnight culture stock, incubated at 37°C 
until OD600 was  0.8 and decreased the temperature to 25°C. As soon as OD600 was  1.1 
we induced protein expression with 30 µM IPTG. After expression for 4 h at 25°C the cells 
were harvested by centrifugation at 4,000 rpm for 20 min and the cell pellet was frozen in 
liquid N2 and stored at -80°C. 
 
IIC2 protein expression 
 In contrast to VC1, this protein is stable and can be expressed in large amounts ( 30 
mg/L). Therefore, protein expression can be performed overnight and in a smaller volume of 
one liter T7 media. The expression was started as soon as OD600 was  0.8 and induced with 
30 µM IPTG at 30°C. The next morning cells were collected by centrifugation at 5,000 rpm 
for 20 min. The cell pellet was drenched in liquid N2 and also stored at -80°C. 
 
Gs protein expression 
 Due to the fact that the expression level for Gs was not exuberant ( 3 mg/L) we 
inoculated 10-12 L T7 media at 37°C with the overnight culture stock. Expression of Gs was 
started at OD600 of 0.45 with 50 µM IPTG and continued at 30°C overnight. After 18 h the 
cells were harvested at 4,000 rpm for 20 min, frozen in liquid N2 and stored at -80°C. 
 
Cell lysis 
The lysis buffers used for cell lysis are listed in the following table: 
 
Protease inhibitors (PI) are: 
PTT          1,000x        LL             1,000x 
TPCK        320 mg        Leupeptin      16 mg 
TLCK        320 mg        Trypsin inhibitor II-L   16 mg  
DMSO        ad 5 ml        H2Odest        ad 10 ml 
PMSF        350 mg 
Isopropyl alcohol           ad 10 ml     
 
Lysis buffer VC1 IIC2 Gs 
NaCl 120 mM 50 mM 100 mM 
Tris-HCl pH 8.0 50 mM 50 mM 50 mM
 
-ME 1 mM - 20 mM 
DTT - 2 mM - 
protease inhibitors  1x 1x 1x (only PTT, not LL) 
H2Odest ad 1500 ml ad 200 ml ad 1000 ml 
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 At the beginning we tried different cell lysis methods, e.g. homogenization with UltraTurrax 
(TP 18-10, IKA Werk) or ultrasound (Bandelin Sonoplus, Bandelin Electronics). However, the 
best lysis was achieved by homogenizing the frozen cell pellet together with lysis buffer with 
a Braun hand blender for 2 min until a viscous suspension without any chunks was achieved. 
Half of the lysis buffer was used to blend the cells the first time. Then lysozyme (freshly 
prepared in lysis buffer) was added in a final concentration of 0.2 mg/ml and the suspension 
was slowly stirred for 40 min at 4°C. All the following steps were performed at 4°C, using a 
cold room or refrigerator. A good lysis was achieved as soon as the suspension showed a 
mucous layer on top.  
 Then DNase I (also freshly prepared in lysis buffer) was added to the solution in a 
concentration of 8-10 µg/ml together with 1 mM MgCl2 to break down the DNA. After stirring 
20 min the mucous layer was dissolved and the suspension was centrifuged using 
ultracentrifugation at 35,000 rpm for 35 min. The obtained supernatant was applied to a 
protein purification column and the pellet was frozen in liquid N2. The frozen pellet was again 
blended for 1 min with one quarter of lysis buffer and stirred for 20 min after adding 8-10 
µg/ml DNase I and 1 mM MgCl2. After ultracentrifugation we used the supernatant for protein 
purification and the remaining pellet was discarded. The second lysis was necessary to 
obtain a higher protein yield. 
2.2.1.8. Protein purification 
 After cell lysis the supernatant contains all proteins that are expressed in the cell. To 
obtain a pure and functional protein, different purification steps had to be carried out 
depending on the protein. This chapter deals with the buffer solutions and columns used for 
purification of VC1, IIC2 and Gs. 
 
Purification of VC1 
 The protein carries a hexahistidine tag at the N-terminus. Therefore, it can be purified 
using an affinity column for hexahistidine. We first tried to use a HisTrap FF 5 ml column, but 
the purification could be improved using Talon chromatography, because less contaminants 
were retained with this resin, increasing protein yield. An empty column was packed with 10 
ml Talon resin, washed with H2Odest and equilibrated with 100 ml VC1 lysis buffer.  
 The supernatant ( 1200 ml) was applied to the column using gravity flow and the flow 
rate was adjusted to  2 ml/min. After loading (in general around 10 h) the column was 
washed with 50 ml Wash I buffer, followed by 25 ml Wash II buffer to clean the resin from 
non-specifically bound protein. Elution was started using Elution buffer and 2 ml fractions 
were collected. Fractions were analyzed using SDS-PAGE (2.2.1.9) and the fractions 
containing VC1 were pooled together. Pooled fractions ( 12 ml) were diluted with buffer A to 
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decrease the final imidazole concentration to < 30 mM. The diluted protein solution was then 
further purified using two ion exchange columns. 
 
Wash I buffer  pH 8.0    Wash II buffer  pH 8.0    Elution buffer    pH 8.0 
NaCl    500 mM     NaCl     50 mM    NaCl    120 mM 
Tris-HCl     50 mM     Tris-HCl    50 mM    Tris-HCl     50 mM 
-ME        1 mM     -ME         1 mM    -ME        1 mM 
PI          1x     PI          1x    PI          1x 
H2Odest        ad 50 ml     H2Odest       ad 25 ml    Imidazole  100 mM 
                        H2Odest      ad 50 ml 
 
 A HiTrap Q FF 1 ml column was used as a precolumn to bind contaminating proteins and 
the Mono S 5/50 GL column was used for VC1 binding. Both columns were equilibrated with 
10 ml buffer A. Protein solution was loaded onto the columns using a Superloop and a flow 
rate of 0.2 ml/min (Äkta FPLC). The columns were washed with 10 ml buffer A. The gradient 
elution runs only through the Mono S column and bypasses the HiTrap Q column. A fast 
gradient is run for 5x column volumes (CV) to 20% buffer B, followed by a slow gradient for 
40x CV to 100% buffer B and fractions of 1 ml were collected. 
 
Buffer A*      pH 7.0        Buffer B*       pH 7.0    
HEPES       20 mM        Buffer A + 1 M NaCl    250 ml 
MgCl2         2 mM 
EDTA pH 8.0           1 mM 
DTT          2 mM 
PI                1x        *buffers are filtered (0.22 µm filter) 
H2Odest           ad 350 ml  
 
 In order to determine the fractions of interest, collected samples were applied to SDS-
PAGE (2.2.1.9). The fractions containing VC1 were pooled together and concentrated using 
a centrifugal filter device. For crystallization work only fresh and not frozen concentrated VC1 
was used.  
 
Purification of IIC2 
 Since IIC2 was expressed as a tag-less protein, we could not use affinity chromatography. 
Therefore we started with an anionic exchange column and used a self-filled 50 ml 
Q Sepharose FF column. The supernatant after cell lysis was first filtered through a 0.45 µm 
filter to prevent clogging of the column. Flow rate was 5 ml/min. The column was equilibrated 
with 100 ml buffer D, loaded with the cell extracts ( 200 ml) and washed with 100 ml 
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buffer D. A linear gradient from 50 to 350 mM NaCl (200 ml) was started, followed by a 
second linear gradient step (100 ml) to 1 M NaCl and 7 ml fractions were collected. 
 
Buffer D       pH 8.0       Buffer E         pH 8.0 
Tris-HCl       50 mM       Tris-HCl        50 mM 
NaCl        50 mM       NaCl              1 M 
DTT          2 mM       DTT            2 mM 
PI                1x       PI              1x 
H2Odest            ad 1.0 L       H2Odest                ad 1.0 L 
 
 Peak fractions were determined by SDS-PAGE (2.2.1.9) and the pooled fractions were 
loaded on a 50 ml HAP column (2.1.1) with a flow rate of 3 ml/min (equilibrated with buffer 
D). The column was washed with 100 ml buffer D and a gradient of 0 – 300 mM Na2HPO4 (in 
buffer D, pH 8.0) for 150 ml was run. IIC2 was eluted at  100 mM Na2HPO4 concentration 
and collected in 9 ml fractions. The pooled fractions were dissolved in 3.6 M (NH4)2SO4 to a 
final concentration of 1.2 M (NH4)2SO4. A hydrophobic chromatography was applied using a 
HiTrap Phenyl 5 ml FF column. The protein solution was loaded onto the equilibrated 
column, washed with 75 ml buffer A, and linear gradient elution (50 ml) was started by the 
replacement of buffer A (1.2 M (NH4)2SO4) against buffer B (no (NH4)2SO4), 3 ml fractions 
were collected. 
 
Buffer A       pH 8.0       Buffer B         pH 8.0 
Tris-HCl       50 mM       Tris-HCl         50 mM 
MgCl2         1 mM       MgCl2             1 mM 
EDTA, pH 8.0       1 mM       EDTA, pH 8.0           1 mM 
PTT                1x       PTT                    1x 
(NH4)2SO4        1.2 M       H2Odest             ad 400 ml 
H2Odest           ad 300 ml  
 
 The pooled fractions ( 30 ml) containing IIC2 were filled into a dialysis membrane 
(MWCO 10 kDa) to remove (NH4)2SO4 by dialysis with 3x 1.0 L dialysis buffer.  
 
Dialysis buffer     pH 8.0  
HEPES       20 mM 
MgCl2         2 mM 
DTT          1 mM 
EDTA, pH 8.0       1 mM 
PI                1x 
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 The protein sample was concentrated to  2 ml and diluted in buffer D to a final volume of 
50 ml. The first procedure with 50 ml Q Sepharose FF has to be repeated and afterwards the 
peak fractions were evaluated by SDS-PAGE (2.2.1.9). Fractions of interest were pooled 
together and concentrated using a centrifugal concentrator with a 10 kDa MWCO (2.1.3). 
 
Purification of Gs 
 The protein was expressed with a hexahistidine tag at the C-terminus. After cell lysis 
supernatant was therefore first purified by affinity chromatography using 2 tandemly arranged 
HisTrap 5 ml columns. The columns were washed with 100 ml H2Odest, followed by 
equilibration with Gs lysis buffer. The lysis buffer contains high concentration of reducing 
agent -ME, and therefore, the columns turn their colour from blue to light violet. We also 
used 10 ml Profinity IMAC Ni-charged resin that was more resistant against -ME 
(compatible up to 30 mM concentration) which did not show any change in colour. However, 
both columns showed sufficient binding affinity. The supernatant was applied to the columns 
with a 2 ml/min flow rate and afterwards the columns were washed with 100 ml Wash buffer 
to remove non-specific bound contaminants. Elution of his-tagged protein was started by 
slow gradient elution from 0 to 150 mM imidazole for 200 ml, using Buffer A and B. 
Compositions of the buffers are shown below: 
 
Wash buffer  pH 8.0    Elute buffer A  pH 8.0    Elute buffer B    pH 8.0 
Imidazole    10 mM     Tris-HCl    50 mM     Tris-HCl     50 mM 
NaCl    500 mM     -ME       20 mM    -ME      20 mM 
Tris-HCl     50 mM     Glycerol       10% (v/v)    Glycerol     10% (v/v) 
-ME      20 mM     PTT           1x    PTT         1x 
Glycerol    10% (v/v)     H2Odest       ad 400 ml    Imidazole  150 mM 
GDP       25 µM                 H2Odest     ad 400 ml 
NaF      10 mM          
AlCl3        30 µM 
MgCl2       4 mM 
PTT         1x 
H2Odest      ad 400 ml  
 
 The protein solution was collected in 5 ml fractions, run on SDS-PAGE (2.2.1.9), and the 
fractions containing Gs were further used for anion exchange chromatography using a 
HiTrapQ 5ml column. The column was equilibrated with 50 ml buffer C. The protein solution 
was diluted with buffer C in a 1:1 ratio to decrease the -ME concentration and then loaded 
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onto the HiTrapQ column with a flow rate of 2 ml/min. The column was then washed using 
2x CV of buffer C.  
 
Buffer C*      pH 8.0        Buffer D*       pH 8.0    
Tris, pH 8.0 (RT pH 7.7) 50 mM        Buffer C + 1 M NaCl   250 ml 
DTT          1 mM 
Glycerol          10% (v/v)        *buffers were filtered (0.22 µm filter) 
H2Odest        ad 250 ml  
 
A gradient from 0 – 250 mM NaCl was run for 10x CV, followed by a gradient to 1 M NaCl 
for 10x CV, using buffer C and D and 3.5 ml fractions were collected.  
 Fractions were used for SDS-PAGE analysis (2.2.1.9) and the Gs-containing fractions 
were pooled together. KH2PO4/ K2HPO4 = KPO4-buffer 1 M (pH 8.0) and GDP were added 
to the solution in a final concentration of 10 mM and 5 µM, respectively. The protein solution 
was then loaded onto a 50 ml HAP column (2.1.1) that was preequilibrated with 50 ml buffer 
E. The flow rate was set at 2 ml/min and after a wash for 2x CV, elution was started by first 
running a gradient from 10 – 250 mM KPO4-buffer for 10x CV and then to 500 mM KPO4 for 
5x CV.    
 
Buffer E*      pH 8.0          Buffer F*         pH 8.0    
NaCl          100 mM          NaCl        100 mM 
Tris, pH 8.0 (RT pH 7.7)  100 mM          Tris, pH 8.0 (RT pH 7.7)   100 mM 
DTT          2 mM          DTT                2 mM 
GDP           5 µM             GDP             5 µM 
Glycerol          10% (v/v)          Glycerol             10% (v/v) 
KH2PO4/ K2HPO4        10 mM          KH2PO4/ K2HPO4        500 mM 
H2Odest             ad 500 ml          H2Odest                  ad 500 ml 
*buffers were filtered (0.22 µm filter) 
 
 Samples of the 3 ml fractions were run on 
SDS-PAGE (2.2.1.9); the important fractions 
were pooled together and concentrated using a 
centrifugal filter device with a 10 kDa MWCO. 
 To remove KPO4  the protein solution was 
placed in a dialysis membrane with a 10 kDa 
MWCO and 3x dialysed in 1.0 L buffer G. 
 
      Buffer G             pH 8.0 
      NaCl          50 mM 
      HEPES              20 mM 
      -ME            1 mM 
      EDTA                 1 mM 
      MgCl2                5 mM 
      H2Odest                             ad 1.0 L 
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 For crystallization, Gs had to be activated by GTPS and digested to a smaller protein 
fragment of  37 kDa in order to remove floppy ends that may prevent formation of a stable 
heterotrimeric complex. For this purpose dialysed and concentrated protein was diluted with 
an equal volume of activation buffer (HEPES 40 mM, pH 8.0; MgCl2 4 mM, -ME 1 mM, NaCl 
200 mM) and GTPS was added at a concentration of 500 µM. The protein was incubated for 
2 h at 30°C and afterwards, digestion was started by addition of 1 mg/ml trypsin (TPCK-
treated) to make a final concentration of 5 µg/ml. To control digestion, the solution was 
incubated for 2 h on ice. Imidazole and PTT was added to a final concentration of 5 mM and 
1x PTT, and the protein solution was loaded onto a preequilibrated 0.8 ml Ni-NTA or Talon 
gravity column. The pass-through was collected and then the column was washed with 5 ml 
wash buffer (Tris-HCl 50 mM, pH 8.0; NaCl 120 mM, Imidazole 8 mM). Pass-through and the 
wash were pooled together, diluted to 50 ml with buffer A and purified using anionic 
exchange chromatography. A MonoQ 5/50 GL column was equilibrated with buffer A and 
after protein loading; a gradient to 300 mM NaCl for 25 ml was run. Isocratic elution at 
300 mM followed for 5 ml and at the end gradient elution to 1 M NaCl for 10 ml.  
 
Buffer A*      pH 8.0        Buffer B*       pH 8.0    
HEPES       20 mM        Buffer A + 1 M NaCl    250 ml 
MgCl2         2 mM 
EDTA pH 8.0           1 mM 
DTT          2 mM 
H2Odest        ad 500 ml        *buffers were filtered (0.22 µm filter) 
 
The fractions (1 ml) were collected and further characterized on SDS-PAGE (2.2.1.9) and 
concentrated with a Vivaspin 10 kDa MWCO.  
2.2.1.9. Protein biochemical methods 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 Purification quality was assessed using SDS polyacrylamide gel electrophoresis. A 
complex protein sample can be characterized and separated into protein fractions dependent 
on their size due to their electrophoretic mobility (Laemmli, 1970). SDS is added to the 
solutions and gels and binds to the proteins to denature the protein structure and to achieve 
an identical (negative) charge to mass relationship of the proteins. Therefore, protein 
mobility, in theory, depends on the size of the protein and the pore diameter of the gel. The 
pore diameter is influenced by the polymerization degree of acrylamide to bis-acrylamide. 
Pore size decreases with increasing amount of acrylamide. We used either 4-20% (m/v) 
Ready Gel Tris-HCl, Bio-Rad (precast gels) or 15% (m/v) separating gel (hand-casted gels). 
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Hand-casting of the gels and subsequent gel electrophoresis was achieved using the casting 
stands and vertical electrophoresis system Mini-PROTEAN® Tetra Cell (Bio-Rad). First the 
separating gel was loaded into the casting stands, leaving a 2 ml gap on top that was filled 
with isopropanol. After  45 min the separating gel was polymerized and the gap was filled, 
after removal of isopropanol, with loading gel plus a pocket forming comb. Gels were 
inserted into the vertical electrophoresis chamber.  
 
15% m/v separating gel     2 small gels        loading gel    2 small gels  
Buffer A*, pH 8.8                  4 ml           Buffer B*, pH 6.8     2.5 ml 
Acrylamide 30% (m/v)                   8 ml         Acrylamide 30% (m/v)          1 ml 
APS 10% (m/v) (in water)              66.7 µl           APS 10% (m/v)              100 µl 
TEMED                    6.7 µl         TEMED                       6.7 µl 
Glycerol 50% (v/v)        1.06 ml    H2Odest             6.5 ml 
H2Odest                 2.8 ml          
 
 Buffer A*:               Buffer B*: 
 Tris-HCl, pH 8.8      1.5 M     Tris-HCl, pH 6.8    0.5 M 
 SDS 10% (m/v)        4 ml      SDS 10% (m/v)              4 ml 
 H2Odest           100 ml     H2Odest         100 ml 
 
The protein sample was mixed with 2x Laemmli buffer at a 1:1 ratio to a final volume of 20 µl 
and then heated for 3 min at 95°C. The samples and a protein standard were applied to the 
gel pockets and separated at 150 V in 1x running buffer. After gel electrophoresis the gels 
were stained with Coomassie or blotted on nitrocellulose membrane for Western Blot. 
 
10 x running buffer     pH 8.3      2x Laemmli buffer       pH 8.0 
Tris-HCl, pH 8.3        250 mM        Tris-HCl, pH 8.0                    25 mM 
Glycine               1.92 M         DTT                  200 mM 
SDS                   1% (m/v)         SDS               2.5% (m/v) 
H2Odest             ad 10.0 L     Glycerol                         5% (v/v) 
                      Bromphenolblue                0.01% (m/v) 
                  Urea                8 M 
                  H2Odest            ad 60 ml 
 
Coomassie blue - staining 
 To detect seperated proteins on the SDS-PAGE gel, Coomassie staining was used. The 
gels were shaken for  30 min in Coomassie staining solution and afterwards a destaining 
solution was used to remove the blue background color from the gel.  
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Coomassie staining solution             Destaining solution 
Coomassie Blue R 250           1.5 g         Acetic acid                 100 ml  
Methanol             455 ml         Methanol                    300 ml 
Acetic acid                90 ml         H2Odest                       ad 1.0 L 
H2Obidest                  ad 1.0 L 
 
 The destaining solution was changed every 20 min until a good detection of protein bands 
could be seen. The gels were dried on filter paper at 80°C under vacuum or between two 
cellophane sheets using a Gel Air Drying system (Bio-Rad). 
 
Western Blot 
 Proteins, separated via SDS-PAGE can be further analyzed by transfer to a nitrocellulose 
or polyvinylidene difluoride (PVDF) membrane. The blotting of proteins to a membrane is 
referred to as Western Blot. The protein bands on the gel were transferred to a nitrocellulose 
membrane (2.1.3) using a tank transfer system (Mini Trans-Blot® Cell, Bio-Rad), filled with 
blotting buffer. The transfer was achieved after 120 min at 0.15 A current and can be 
checked by application of Ponceau S, a dye that stains the protein bands on membranes in a 
reversible manner. The membrane was then incubated with a specific primary antibody 
(2.1.2), followed by a horseradish peroxidase secondary antibody (2.1.2) that binds to the 
primary antibody and can be photocemically detected - showing only “the protein of interest”. 
TBS buffer (1x) substituted with Tween 20 (TBS-T buffer) and with or without addition of 
skimmed milk (5% m/v) was used for the application of the antibodies and during the wash of 
the membranes. In our case, we used a hexahistidine antibody as primary antibody to control 
expression levels of the hexahistidine tagged proteins in the protein solutions.  
 
Blotting buffer                 10x TBS buffer      pH 7.6 
Tris                 3 g        Tris-HCl, pH 7.6                  200 mM 
Glycin                 14 g         NaCl                    1.37 M 
Methanol                 200 ml         H2Odest           ad 1.0 L 
H2Odest             800 ml                      
                  TBS-T buffer       pH 7.6 
                  Tween 20          1 ml  
                  TBS buffer 1x           ad 1.0 L  
 
The exact procedure is explained in detail in the supplementary data (8.1). 
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Bradford protein assay 
 For quantification of the pure protein after protein purification we used the colorimetric 
Bradford protein assay (Bradford, 1976). In principle, the protein was detected via interaction 
of positively charged amino acids with the negatively charged Coomassie dye. By binding to 
the protein the originally red form of Coomassie changes to Coomassie blue, shifting the 
absorption maximum from 465 to 595 nm. Protein concentration was detected by measuring 
the extinction at 595 nm (Biophotometer, Eppendorf), using BSA as calibration standard.  
Either 100 µl protein sample, or BSA standard (1-10 µg BSA/100 µl H2Obidest) or buffer (as 
blank) were mixed with 1 ml Bradford dye (Bio-Rad), incubated for 5 min and then measured 
at 595 nm. 
 
2.2.2. Crystallization 
All crystallization work was done at the University of Montana under supervision by Drs. 
Steve Sprang (Ph.D.) and Tung-Chung Mou (Ph.D.).  
2.2.2.1. Complex formation 
A ternary complex of H6-VC1 (580), IIC2 or IIC2 mutant (K1014N) and Gs-GTPS was 
formed by mixing the three purified proteins in the following order (no specific time interval):  
C1 + C2 → Gs. 
An excess amount of C1 ( 37.5 µmole) was used relative to C2 and Gs ( 25 µmole 
each). The higher concentration of C1 and the order of mixing prevented that C2 and Gs 
form a complex in the absence of C1. The formed complex was then incubated on ice for 30 
min, with or without the addition of 200 µM FS or FS analog. Afterwards the complex was 
isolated from the single proteins in the absence or presence of FS by tandem gel filtration. 
The sample was first applied to a Superdex 75 gel filtration column to which a Superdex 200 
had been attached.  
 
gel filtration buffer pH 8.0 (mM)  
HEPES            20 
MgCl2         2    
EDTA pH 8.0       1 
DTT          2   
NaCl          100 
GTPS         0.01 
(FS/FS analog       0.025)         
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The FPLC fraction collector collected 300 µl fractions that were resolved on a 4-20% (m/v) 
TRIS-glycine precast gel. Fractions containing only ternary complex were pooled together 
and after adding 5 mM DTT, 500 µM GTPS, with or without FS or FS analog, the protein 
complex was concentrated to  8 mg/ml with Vivaspin 30K. 
  
2.2.2.2. Crystal growth 
To grow crystals, we set up 24-well crystallization plates. We used either VDX plates for a 
hanging drop setup or Cryschem plates for a sitting drop setup (2.1.3). Figure 5 illustrates the 
different crystallization setups.  
 
 
Figure 5. Crystallization setup. In the hanging drop crystallization plates, the protein solution (1 µl) is hanging 
on the  cover lid. In contrast, the protein solution can also “sit” on a concave drop post using sitting drop plates. 
 
The reservoir solution contained a mixture of: 
- polyethylene glycol (PEG) 8000, in different concentrations (7.0 – 8.0% v/v) 
- NaCl 0.5 M and 
- 0.1 M MES, with different pH (5.3 – 5.7).   
 
See section G4 for a better understanding of the reservoir solution preparation where a 
protocol for the setup of a crystal try is shown. The reservoir solution was freshly prepared 
and directly mixed inside one well. The 24 well plates had to be prepared before applying the 
reservoir solution. With a hand syringe vacuum grease was applied to the rim of the 24 wells. 
The grease is used to form a closed environment inside the well. As soon as 1 µl of protein 
solution was applied to the lid (hanging drop version) or to the drop post (sitting drop 
version), the lid is tightly pushed onto the greased crystal tray to prevent any water loss. The 
trays were incubated at 16°C in a special temperature controlled incubator. To prevent strong 
movement of the trays inside the incubator, they were placed in special racks. Formation of 
micro crystals and large crystals were monitored by light microscopy. 
H2O 
reservoir solution 
H2O 
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2.2.2.3. Crystal collection and soaking    
After optimal crystal growth, crystals were picked using a cryo loop (2.1.3) with a diameter 
of 100 - 200 µm and cryoprotectant. To measure nucleotide – crystal interactions large 
crystals were soaked with 2 mM MANT-ITP/TNP-GTP and 3 mM MnCl2 (in cryoprotectant) 
for at least 2 h at room temperature and then harvested and stored in liquid nitrogen.  
 
Cryoprotectant  
PEG 8000                9% (v/v) 
PEG 400                      30% (v/v) 
MES pH 5.4               100 mM  
NaCl                 500 mM 
HEPES (NaOH) pH 8.0                20 mM 
EDTA                     1 mM 
DTT                     2 mM 
MP-FS                      200 µM 
GTPγS                      100 µM 
MANT-ITP                        2 mM 
MnCl2                    3 mM 
2.2.2.4. Structure determination and model refinement 
Diffraction data sets were collected at the Stanford Synchrotron Radiation Lightsource 
SSRL-SMB-MC 9-1 beamline by oscillation method (1°/frame, 60 s/frame). The incident 
beam wavelength was 0.9795 Å. The images were processed using HKL2000 package 
(Otwinowski and Minor, 1997). Due to anisotropy of the plate-type crystal, data with l index 
> 21 were excluded from the data set. Structures were determined by molecular replacement 
using the structure of the Gs-GTPS:VC1:IIC2 complex (PDB code: 1AZS) as the initial 
phasing model (Tesmer et al., 1997). Atomic positions and thermal parameters of the mAC 
structure were refined by Refmac5.5 using the CCP4 program suite (Collaborative 
Computational Project, 1994). MANT-ITP/TNP-GTP and Mn2+ ions in the structure were 
located in the weighted |Fo|-|Fc| omit map computed with phases from the refined model. The 
model was iteratively improved by manual refitting into weighted 2|Fo|-|Fc|map using the 
computer graphics program Coot (Emsley and Cowtan, 2004) and subsequent refinement 
cycles with CCP4. The visualization of the refined crystal structure was created with Pymol 
(DeLano, 2002).  
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2.2.3. Molecular modelling 
 For evaluation of AC inhibition, as well as fluorescence and crystallographic 
measurements, structure models for the complex of VC1/IIC2 with MANT-ITP and MANT-
GTP were generated via docking studies and subsequently refined by molecular dynamics 
simulations. The computer models for the two MANT nucleotides were constructed using the 
crystal structures of VC1/IIC2:Gs:FS inhibited by MANT-ITP (PDB 3G82) and MANT-GTP 
(PDB 1TL7) as template. In both cases, the new complex was constructed by editing the 
structure of co-crystallized ligand in SYBYL to represent the desired ligand (Tripos, 2008). 
Only the isomer resolved as a co-crystallized component in the crystal structure was used for 
structure determination. Conformational predictions were conducted using the whole C1/C2 
molecule. All atoms were frozen except for the ligand and any residue with at least one atom 
within 8 Å of the ligand to examine the ligand conformational variation. The full complex was 
then protonated in SYBYL: both ligands were assumed to have a fully anionic triphosphate 
tail (net charge = -4), while the receptor valences were assumed to correspond to 
physiological pH, with cationic lysine and arginine residues, anionic aspartates and 
glutamates and all other atoms saturated to neutrality. Unrealistic atomic contacts were 
alleviated by energetically minimizing all hydrogen atom coordinates via the AMBER ´89 
force field and corresponding charges as implemented in the MOE software suite. Based on 
the assumed valences, Gasteiger-Marsili partial charges were assigned to all atoms 
(Gasteiger and Marsili, 1978). The system was permitted some modest relaxation via an 
11 ps molecular dynamics simulation in SYBYL (1 ps warming from 0 to 300 K, followed by 
10 ps thermal equilibration) in which the ligand and all receptor residues within 8.0 Å of the 
ligand were left conformationally mobile. The resulting relaxed complex structures were then 
optimized within SYBYL default convergence thresholds via molecular mechanics.  
  
2.2.4. Electrophysiology 
The electrophysiological measurements on cardiomyocytes were carried out at the 
Department of Pharmacology, University of Cologne, under supervision of Prof. Dr. Stefan 
Herzig. We studied the effect of different MANT nucleotides on basal L-type calcium current. 
Cardiomyocytes were freshly isolated from a common WT mouse line C57BL/6 mice on the 
day of WC measurement.  
2.2.4.1. Animals 
The following materials were used for the breeding of WT C57BL/6 mice: 
 Makrolon cages with wire lids and water bottles, Tecniplast, Italy 
 sterile standard diet and animal bedding fiber, Altromin, Lage 
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All experiments with animals complied with respective laws and local regulations 
regarding animal care. Due to the fact that mice were also used for transgenic breeding their 
WT background was checked via genotyping, using standard PCR technique. 
2.2.4.2. Isolation of murine cardiomyocytes 
The isolation of murine ventricular myocytes was performed using enzymatic dissociation 
(Wolska and Solaro, 1996; Beetz et al., 2009). The heart was perfused through the coronary 
arteries to digest the myocardium. We used 3-9 months old mice that were sacrificed by 
cervical dislocation. To prevent thrombus formation in the aorta we injected heparin (final 
concentration 500 I.E./ml in sterile 0.9% m/v NaCl) intraperitoneally 30 min before the mice 
were sacrificed (7.5 I.E./g body weight). The heart was immediately excised, rinsed in 
solution A and the aorta ascendens was cleaned from fat and connective tissue before 
canulation with a blunt injection needle. The aorta was attached to the injection needle with a 
sewing thread. Afterwards the canulated heart was mounted on a Langendorff apparatus and 
perfused with solution B.  
 
solution level that regulates the perfusion rate
circulating heating bath
double-walled
column with
solution B
oxygen supply
three-way valve to
change solution
organe bath
with heart
solution C 
 
 
Figure 6. Langendorff setup. On the left picture a Langendorff column and an organ bath, filled with solution B 
is illustrated. The right picture shows the canulated heart, hanging on a three-way valve. 
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The Langendorff apparatus is a double-walled column that is regulated by a water bath 
and can be supplied with oxygen (Figure 6). Therefore, the heart can be perfused and 
oxygenated at 37°C. The flow rate was controlled by the height of the column. After 5 min of 
perfusion, solution B was removed through a three-way valve and exchanged with solution 
C. Solution C contains collagenase type 1 and 2 that starts the enzymatic digestion of the 
connective tissue in the heart. The heart was perfused with solution C for 10-15 min, 
depending on the appearance of the heart and the perfusion rate. Due to increased digestion 
over time, the perfusion rate increased and the heart became discolored. The heart was 
removed from the Langendorff apparatus and the ventricles were separated from atrial tissue 
in 10 ml solution D. With a scalpel, the ventricles were cut into small pieces. In order to 
separate single cells from the tissue, the small pieces were homogenized with a transfer 
pipette by gentle agitation for 2 min. The large tissue chunks were separated from the single 
cells using nylon cheesecloth with a pore diameter of 250 µm. Single cells were incubated in 
solution D (100 µM CaCl2 in solution B) for 20 min at room temperature to adjust the cells to 
a calcium rich solution. Step-wise, the calcium concentration was increased by removal of 
5 ml solution D and addition of 10 ml solution E (200 µM CaCl2 in solution B). After an 
additional 20 min of incubation, solution E was exchanged for solution F (400 µM CaCl2 in 
solution B). Afterwards, the cells are ready for electrophysiological measurements and can 
be used 5-6 hours, when stored at room temperature. 
Solution A (with NaOH)  pH 7.4        Solution B   
NaCl        133 mM        BSA             500 mg 
KCl        4 mM        solution A      ad 500 ml 
NaH2PO4 x 1H2O     1.2 mM         
MgSO4 x 7H2O     1.2 mM        Solution C 
HEPES         10 mM        Collagenase type 1        75 U/ml 
glucose         12 mM        Collagenase type 2        75 U/ml 
H2Odest                     ad 1.0 L        solution B       ad 200 ml 
 
2.2.4.3. Patch clamp 
A valuable tool in the analysis of excitable membranes is the patch-clamp technique 
(Numberger and Draguhn, 1996). It is used to measure membrane currents and membrane 
capacitance. Already in 1791, Luigi Galvani postulated that muscles work via electrical 
signals. However, it took almost a century until electrophysiological measurements were 
established by using zinc electrodes to detect nerve and muscle current. At the end of the 
1930s, Cole and Curtis established the voltage-clamp technique to measure the conductivity 
of membranes. This technique was later used by Hodgkin and Huxley to show the formation 
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of an ion induced action potential in the giant axon of squid (Hodgkin and Huxley, 1952b; 
Hodgkin and Huxley, 1952a). But to identify single channels it took an additional 20 years 
until Neher and Sakmann developed the patch clamp technique (Hamill et al., 1981). They 
were awarded the Nobel Prize in Physiology and Medicine in 1991 “for their discoveries 
concerning the function of single ion channels in cells”. The idea is that a membrane patch is 
shielded from the environment by a tightly bound glass pipette expressing a high resistance 
on the cell surface. A very close seal of the pipette to the membrane is reached when the 
electrical resistance is > 1 G, referred to as gigaseal. With the development of tight seals, 
the electrical noise could be diminished and the development of more sensitive amplifier 
technology made it possible to measure even picoampere (pA) currents. Different patch 
clamp configurations are used nowadays; the most important are cell-attached, inside-out, 
outside-out and whole cell (WC) (Hamill et al., 1981). In our case we used the cell-attached 
configuration followed by WC configuration. 
The following figure shows a schematic WC patch clamp setup. 
 
 
 
Figure 7. Scheme of Patch clamp setup in WC configuration. An action potential can be initiated by 
application of a depolarizing pulse from the pulse encoder and computer, respectively. In our case this opens 
Ca
2+
 channels and the change in membrane potential is detected by the bath and pipette electrode of the 
preamplifier, further transmitted to the amplifier and converted into digital data via the AD converter. The 
computer records these digital data. 
2.2.4.4. Whole cell configuration 
Whole cell recordings were performed at room temperature (22-25°C) using the WC 
configuration as shown in Figure 7. Optical control of the cells during the entire experiment 
was carried out with an inverse microscope (2.1.1) using a 100-fold and 400-fold 
magnification. The experiment was conducted within a Faraday cage and the microscope 
was operated with a battery to prevent any interference by electromagnetic noise.  
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Cells (300 µl, in solution F) were placed in disposable Petri-dishes and superfused with an 
external bath solution (ad 3 ml). The bath electrode connected to the microelectrode amplifier 
is a reference electrode that was placed into the bath solution. The measuring electrode was 
also connected to the preamplifier and positioned in the glass pipette. Pipettes (2-3 MΩ) 
were filled with pipette solution. The solutions were prepared freshly on the day of 
measurement.  
MANT nucleotides were added directly to the pipette solution in a concentration of 1 µM. 
The advantage of the whole-cell configuration was the application of impermeable 
substances into the cells via the pipette solution. In our case, it was possible to apply a 
specific concentration of MANT nucleotides directly into the cytoplasm.  
 
Bath solution         pH 7.4     Pipette solution*                pH 7.2 
NaCl          137 mM     CsCl           120 mM 
CsCl           5.4 mM     MgCl2              1 mM 
CaCl2             2 mM     Mg
2+-ATP             4 mM 
MgCl2        1.25 mM     HEPES (with CsOH)        5 mM 
glucose            10 mM 
HEPES (with NaOH)      10 mM     *was filtered through a 0.22 µm filter 
 
Positioning of the glass pipette was achieved using a micromanipulator (2.1.1) that was 
adjustable in 3 directions. Any offset potential in consequence of differences between the 
pipette and bath solution were corrected by the main amplifier as soon as the pipette touched 
the bath solution. It is important that these fluctuations are eliminated before seal formation.  
The pipette was placed very close to the cardiomyocyte. As soon as the pipette resistance 
increased and a light reflection on the cell surface was visible, soaking through a flexible tube 
connected to the pipette holder was accomplished. The previously applied over-pressure 
inside the pipette (2.2.4.5) was reduced, the pipette resistance further increased and the cell 
membrane was slowly soaked onto the pipette tip and a gigaseal (2-5 G) was established. 
The pipette was then in the cell-attached configuration and allowed single-channel 
measurements, if the membrane patch covered a very small area. It is very important that the 
membrane is not ruptured during this procedure. Capacitive transients caused by the pipette 
and the membrane patch have to be compensated with the main amplifier. A negative 
holding potential of -80 mV was applied to the cell to keep the cell in an unexcited state 
before switching to the WC configuration.  
To measure the entity of ion current in the cell we had to penetrate the membrane. Whole 
cell configuration was achieved by gentle suction with a syringe. Thereby, it was necessary 
to keep a tight seal of the pipette to the membrane, expressed by high resistance. If this was 
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not the case, the cell became leaky and lost cytoplasmic constituents. It was then impossible 
to keep a patch for long time. After penetration through the cell membrane, the pipette 
solution was released into the cytoplasm. The volume of the pipette solution is much bigger 
and “dilutes” the cytoplasm reducing essential cytoplasmic factors, like ATP (O'Rourke et al., 
1992; Yazawa et al., 1997). Loss in functional components leads to inactivation of ion 
channels, resulting in “run-down” of ion currents. Another factor that influences “run-down” of 
the cells is an increasing Ca2+ concentration (Belles et al., 1988). Therefore, it was necessary 
to reduce “run-down” of the cells to facilitate long-term whole cell measurements. In our 
case, the pipette solution was optimized by addition of 4 mM Mg2+-ATP and EGTA as Ca2+ 
chelator.  
As soon as a stable WC configuration was achieved, the cells were ready for Ca2+ current 
measurements. Membrane currents were measured with a low-pass filter of 2 kHz. The cell 
remained unexcited as long as a holding potential of -80 mV was applied via the electrode. 
Application of a prepulse to -40 mV for 45 ms was used to depolarize the cell. The prepulse 
inactivates Na+ and T-type Ca2+ channels. Over a time period of at least 15 min, whole cell 
calcium currents were recorded using a protocol that started at a holding potential of -80 mV, 
followed by the depolarizing voltage step to -40 mV for 45 ms and ICa,L was subsequently 
measured using a 200 ms-lasting voltage step to +10 mV. The stimulation frequency was 0.3 
Hz, leaving 3 s between single stimulations. The protocol measured 30 subsequent 
stimulations (sweeps). To identify the voltage that induces the maximal Ca2+ signal in each 
cell and to assure that ICa,L signals are detected, we determined a current - voltage (I-V) 
curve. Therefore, 10 depolarizing pulses from -40 to +50 mV that lasted 140 ms were applied 
after prepulsing from -80 to -40 mV. The current - voltage relationship was assessed after 30 
sweeps at the test potential (+10 mV), i.e. every 2 minutes throughout the experiment.  
Membrane capacitance was measured using a fast depolarizing pulse protocol for 5 ms from 
-40 to -35 mV. The newer pClamp10.2 software was able to calculate membrane 
capacitance (Axon Instruments, Molecular Devices, USA). 
2.2.4.5. Preparation of glass pipettes 
The glass pipettes used for WC experiments were prepared on the day of use. 
Borosilicate glass tubes were cut into  8 cm long capillaries and then fixed in a horizontal 
pipette puller (2.1.1). The shape and the diameter of the pipette tip can be varied to achieve 
a specific pipette resistance of 2-3 M. Therefore, different parameters on the puller were 
changed: heat, the tension of the puller, as well as the time and the speed of the tension. A 
square shaped filament was placed around the middle of the capillary and heated. It melted 
the glass and at the same time the glass was dragged at both sides until it ripped into two 
glass pipettes. The pipettes could not immediately be used after pulling because the tips 
were edged and would damage the cell during sealing. They had to be “polished” and this 
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was achieved by fixing the glass pipette in close distance to a heated filament (custom-made 
microforge). The heat partially melted the tip of the pipette which made the cut smooth and 
even. The ready-to-use glass pipettes were stored in a special, closed jar and were filled with 
pipette solution immediately before use. At the beginning, the pipettes had to be filled from 
the back due to the fact that the tips have a very small diameter (“tip-filling”). A tube with a 
syringe was connected to the back of the pipette and the tip was placed into the pipette 
solution. Via soaking, the tip was filled with solution and through a thin custom-made plastic 
cannula the rest of the pipette solution was filled into the pipette from the back (“back filling”). 
Strong tapping against the side of the pipette removed any air bubbles. The pipette was fixed 
to a pipette holder and located around the measuring electrode. The solution in the pipette 
should cover the tip of the measuring electrode and not exceed a certain level. Otherwise 
liquid can leak into the flexible tube. With the aid of the flexible tube, a connecting valve and 
a syringe a high pressure was created on the pipette. The over-pressure maintained a 
continuous outflow of pipette solution which helped to prevent the pipette tip from becoming 
clogged by any particles in the bath solution. As soon as the pipette is placed into the bath 
solution, pipette resistance was calculated. It was calculated by the pClamp software, but 
can be also calculated using Ohm‟s law (application of a 5 mV pulse).   
2.2.4.6. Electrodes  
We used silver chloride (AgCl) electrodes as bath and measuring electrodes. Before the 
first use and as soon as AgCl electrodes appear polished, they have to be chlorinated. 
Chlorination was achieved by electrolysis.     Ag + Cl-  AgCl +e- 
A clean electrode was connected to an anode of a DC voltage source and placed into 
1 mM KCl. On the electrode surface silver was oxidized to Ag+ and this reacted with the Cl- 
ions to AgCl. We applied a current of 1 mA for chlorination.  
2.2.4.7. Electrophysiology - Data analysis 
The pClamp6 and pClamp10.2.software (2.1.4) were used for data acquisition. Current 
amplitudes were determined by using the difference between the peak current (Ipeak) and the 
lowest current after 200 ms test potential (Ilow). To exclude variability of cell size, current 
density was calculated using current amplitudes in picoamperes (pA) divided by cell 
capacitance in picofarads (pF). To show the reaction of the cell to different MANT 
nucleotides, data was plotted as current density over a 15 min time interval. Statistics and 
data analysis was achieved using GraphPad prism version 5.0. 
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3. Interaction of MANT-ITP with VC1/IIC2 
3.1. Protein purification and crystallization 
3.1.1. Protein purification of VC1 
A substantial drawback of the VC1 protein purification was the low expression level of the 
protein. Initially, we tested several E.coli cell lines (JM109, Origami), but expression with BL 
21 (DE3) yielded the best expression levels. The protein has a molecular mass of  25 kDa. 
The first lysis did not liberate much protein. Therefore, second lysis was very important, but 
the VC1 protein amount was really low and not detectable in a Coomassie stained SDS-gel. 
To ensure that protein expression worked out well, a Western Blot with HIS-antibody was 
carried out at the beginning (8.1). After application of the supernatant to Talon column the 
protein was eluted using an imidazole gradient. As soon as 3 ml of elution buffer had been 
applied to the column, the protein was eluted as shown in Figure 8.  
 
 
 
Figure 8. Lysis and Talon chromatography. The SDS-PAGE shows the cell lysis and 
the first step of protein purification. The second lysis step was necessary, because the 
first lysis did not extract a lot of protein. The elution fractions 3-6 were pooled together 
and applied to the second purification column. Unit for protein marker in kDa. 
 
The Talon resin still binds many contaminants that are eluted together with VC1. They can 
be separated by using a cationic exchange column (Mono S 5/50 GL). Figure 9 shows that 
the protein band at  23 kDa was eluted first, followed by pure VC1 protein. It is very 
important that the whole purification procedure was conducted under cold room-conditions 
(4°C) and in a short time interval of  24 h. The purified protein was never frozen, but used 
immediately for making complex. 
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Figure 9. Ion exchange chromatography using a HiTrap Q/ Mono S column. 
The gel shows only fractions that were eluted from the Mono S column. The 
HiTrap Q column was bypassed. The last three lanes (fractions 25, 29, 35) show 
the pure VC1 protein separated from any contaminants (fractions 15-21). 
 
3.1.2. Protein purification of IIC2 
The tagless protein IIC2 is well expressed in BL21-pREP4 cells and can be detected at 
 23 kDa using SDS-PAGE (Figure 10). Again, a lot of protein is still captured in the cells 
after the first lysis step. At the beginning, protein expression did not work and no protein 
could be detected in the crude cell lysate. Sequencing of the pQE60-ArgC-IIC2 plasmid 
identified a mutation in the promoter region that prevented the expression of the protein, but 
we could obtain new plasmid that did not carry this mutation.  
 
 
 
 
Figure 10. Lysis of IIC2. 
IIC2, indicated by a black arrow, was well 
expressed and the second lysis step still 
released a big amount of protein. 
 
Lane: 
1    after homogenization 
2    Lysis I 
3    Lysis II 
4    pellet 
5    Loading of 1
st
 column 
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Figure 11 shows that after 3 purification steps (anionic exchange, hydroxyapatite column 
and hydrophobic interaction) the protein was still contaminated. 
 
 
Figure 11. Chromatography with 
Phenyl column. 
After three purification steps protein is 
still not totally pure. 
Lane: 
1       Loading 
2       Pass through 
3       Fraction #3 
4       Fraction #5 
5       Fraction #7 
6       Fraction #9 
7       Standard 
8       Fraction #15 
9       Fraction #16 
10 Fraction #19 
 
Therefore, anionic exchange chromatography was applied a second time and the 
purification quality was assessed by SDS Page (Figure 12). It was not possible to totally 
liberate the protein from all the contaminants, but the protein could be used ultimately for 
crystallization, because the contaminants do not disturb the formation of the complex and 
can be avoided by application of the complex to size exclusion chromatography.  
 
 
 
Figure 12.  2
nd
 time Q Sepharose FF column 50 ml. Fractions 16 - 24 contain almost 
pure protein. The protein can be used for crystal growth, because the contaminants are 
insignificant. 
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3.1.3. Purification of Gs 
Due to the fact that the crude lysate contained many contaminants besides Gs, not all of 
the protein was bound to the Ni-IMAC column. Therefore, pass-through and also the wash of 
the Ni-IMAC were applied a second time onto the Ni-IMAC column. The protein was already 
quite pure, when Ni-IMAC column was used as indicated by Figure 13. 
To obtain a pure protein for trypsinization, anionic exchange and hydroxyapatite 
chromatography were additionally applied. The protein was loaded onto anionic exchange 
column after trypsinization and a pure GTPS-activated Gs (Gstryp) was obtained as shown in 
the last lane of Figure 13. 
 
 
 
Figure 13. Ni-IMAC purification. The first purification step was repeated several 
times, because a lot of protein still stayed in the pass through and was not bound to 
the column. The protein was already quite pure (fractions 2-22). The last lane shows 
the trypsinized form of Gs. 
 
Like VC1, protein expression and purification was also evaluated using Western Blot (8.1). 
These proteins were then used to setup the ternary complex for crystallization. 
 
3.1.4. Crystallization of FS-stimulated AC complex 
The ternary complex was formed as explained in Materials and Methods (2.2.2.1) and 
applied to gel filtration to separate the complex from single proteins. Figure 14 shows that 
some fractions (23-32) contain equal amounts of the 3 proteins, indicating the formation of 
the ternary structure. The chromatogram shows a clear peak at a time point that corresponds 
to the MW of the protein complex ( 85 kDa).  
Crystal structure of MANT-ITP mAC complex 
 50 
 
 
Figure 14. Gel filtration of ternary complex. The ternary complex of FS stimulated 
VC1-IIC2-Gs-GTPS was formed and purified by size exclusion chromatography. 
Fractions 23 to 32 were pooled together. The concentrated complex was used to 
prepare crystal trays. 
 
The protein complex was concentrated to  8 mg/ml and used to setup crystal trays. After 
3-4 weeks large crystals were obtained (Figure 15) that were soaked with MANT-ITP and 
TNP-GTP to study nucleotide-protein interaction. The crystals were plate-like and had a 
diameter of  100 µm in the first two directions, but only 5-10 µm in c-axis. In order to gain 
structural information from the plate-like structure, we sent the crystals to the high-intensity 
X-ray beam light of the Stanford Synchrotron Radiation Lightsource (SSRL).  
 
   
Figure 15. Crystals used for MANT-ITP-mAC-complex. Panel A shows a bunch of AC crystals in a hanging 
drop. B displays several crystals that grow on the surface of a sitting drop and panel C shows one crystal that was 
soaked with MANT-ITP, situated on a cryoloop and used for X-ray measurement in the SSRL. 
 
Due to the fact that we also aimed at growing crystals with other FS analogs we tried 
several other crystallization options. Furthermore, we tried to apply MANT-ITP directly to the 
A B C 
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protein solution, instead of soaking experiments with already crystallized FS-AC-complexes. 
One IIC2 mutant (K1014N) is known to stabilize the protein complex. Therefore, we prepared 
complexes with VC1-IIC2 K1014N-Gs, with and without FS. With FS we also obtained very 
large crystals that were used for X-ray measurements. However, when we mixed these three 
proteins together without FS and used MANT-ITP for co-crystallization, most of the protein 
complex precipitated. In contrast to FS, MANT-ITP did not stabilize the ternary complex. 
Therefore, we tried the crystallization of the FS-free complex without the addition of MANT-
ITP. Several times the complex did not form properly, because a lot of protein precipitated 
and the SDS-PAGE after gel filtration did not show an equal ratio of the 3 proteins. But once, 
a ternary complex was formed and after 3 weeks some microcrystals were obtained. 
However, these crystals were too small for structure determination using the SSRL beam 
light.  
We also tried to add FS analogs (1-deoxy-FS, 1,9-dideoxy-FS and 6-acetyl-7-deacetyl-
FS) to identify the interactions of different FS analogs with the catalytic domains (Pinto et al., 
2009). All crystallization trials were unsuccessful, even though we obtained a pure protein 
complex (8.2). Due to the fact that FS analogs are very hydrophobic we had to add the FS 
analogs in DMSO or ethanol yielding a final solvent concentration of 2%. The procedure was 
the same as for obtained crystals that contain FS. It is possible that the solvent composition 
prevented the crystallization of the protein complex or that the complex with “inactive” FS 
analogs was not stable enough for crystallization.  
The soaking experiments with TNP-GTP were successful and we could send some 
crystals for structure determination to the SSRL. TNP nucleotides are excited in the visible 
light range ( = 405 nm) and have an orange color. The crystals showed an intensive orange 
color after 2 h of soaking at 25°C, confirming the presence of TNP-GTP (Figure 16). 
 
 
 
Figure 16. Crystal of FS/Gs stimulated AC after 
soaking with TNP-GTP. The orange color was 
evidence for the presence of TNP-GTP in crystal. 
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 However, even though analysis of the diffraction data gave us a resolution of 3.0 Å and 
completeness of 78%, we could only achieve partial electron densities around the phosphate 
groups of TNP-GTP in the AC binding pocket (Figure 17).  
 
 
 
Figure 17. Difference electron density for TNP-GTP and Mn
2+
. The 
blue wire represents the |Fo|-|Fc| electron density for TNP-GTP and 
Mn
2+
 contoured at 2.5 σ. VC1 and IIC2 are shown as yellow and cyan 
helical structures. Important protein residues are shown as stick model 
(C-atoms grey, oxygen atoms red and nitrogen atoms are colored 
darkblue, respectively). The difference electron density is not sufficient 
for structure determination of TNP-GTP in the active site.  
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3.2. Crystal structure of FS-/Gs activated VC1-IIC2 with MANT-ITP 
 
For a better understanding of the high inhibitory potency of MANT-ITP at ACs 1, 2 and 5 
as well as at the catalytic domains VC1/IIC2 (Table 2, 1.5.1.1), crystallographic studies were 
conducted. The structure was determined by X-ray diffraction using the VC1-IIC2-Gs-GTPS 
crystals soaked with 2 mM MANT-ITP and 3 mM MnCl2 (2.2.2.3). The crystal structure of 
MANT-ITP:Mn2+ was determined up to a resolution of 3.1 Å.  The crystallographic data 
collection and refinement statistics are summarized in Table 3. The coordinates for the 
MANT-ITP:Mn2+ structure were deposited in the Protein Data Bank with the code 3G82.  
 
Parameters                          MANT-ITP:Mn2+ 
Cell constants (Å) 
 a                   117.6 
 b                   133.4 
 c                      70.6 
No. of crystals                     1 
Dmin (Å)                              3.1 
Average redundancy                    3.0 (1.8)a 
Rsym (%)
b                                 17.9 (34.5)  
Completeness (%)                             81.4 (55.1) 
‹I›/‹σ›                                4.5 (1.7)   
Resolution range for refinement (Å)c              15-3.1 
Total reflections used                    15824 
No.of protein atoms                       5645 
No. water molecules                      5 
No. ligand atoms                      106 
rmsd bond length (Å)                0.007 
rmsd bond angle (°)                  1.21 
Rwork (%)
d                          24.1 
Rfree (%)
e                    29.4 
Average B-factor (Å2)                45.2 
 
Table 3. Summary of crystallography data collection and refinement statistics. 
a
 numbers in parentheses correspond to the statistic data from the highest resolution shell. 
b
 Rsym = ∑h∑i | I(h) - I(h)i| / ∑h∑i I(h)i , where I(h) is the mean intensity after rejections. 
c
 Due to anisotropy, data with an l index greater than 21 were omitted from refinement.  
d
 Rwork = ∑h ||Fo (h)| - | Fc (h)||/∑h |Fo (h)|, Fo (h) and Fc (h) are the observed and calculated structure factors, 
respectively. 
e
 5.1% of the complete data set was excluded from refinement to calculate Rfree  
 
The statistics show that only 5 water molecules could be detected, based on the 
resolution of 3.1 Å. The structure shows Gs protein that carries GTPS in the nucleotide 
binding pocket and interacts primarily with the IIC2-subunit. The catalytic domains VC1 and 
IIC2 have the already mentioned pseudo-symmetric arrangement (Tesmer et al., 1997). The 
two subunits form a very large interface between each other, facilitating the binding of FS 
and MANT-ITP. FS is situated at the end of the cleft between VC1 and IIC2 that is closer to 
Gs. Meanwhile MANT-ITP is bound to the catalytic site that converts ATP to cAMP, located 
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on the other site of the VC1:IIC2 interface. Figure 18 illustrates an overview of the ternary 
complex.  
 
Figure 18. Structure of Gs-GTPS and FS-activated catalytic domains VC1:IIC2. 
VC1 and IIC2 are colored wheat and lightpink, respectively. The Gs-domain is colored orange and carries 
GTPS. GTPS, FS and MANT-ITP are shown as stick models. The former two ligands are colored in grey, the 
oxygen atoms of FS are shown in red. MANT-ITP carbon atoms are cyan, nitrogen atoms are darkblue, oxygen 
atoms are red, and phosphorus atoms are green. The two Mn
2+
 ions are shown as orange spheres. Water 
molecules are drawn as blue spheres, Mg
2+ 
ion interacting with the phosphate group of GTPS is shown as pink 
sphere and one chloride ion is shown as green sphere. 
 
MANT-ITP was modeled into the continuous |Fo|-|Fc| map in the binding pocket using the 
structure of the Gs-GTPS:VC1:IIC2 complex as the initial phasing model (Tesmer et al., 
1997) (PDB code: 1AZS). The conformation of the 3‟-O-MANT-ITP is more in agreement with 
the electron density than that of the 2‟-O-MANT-ITP (Figure 19 A). The two diffuse blue 
colored lattices in the difference electron density map are corresponding to the two Mn2+ ions 
where the A-site is weaker than that for the B-site suggesting the Mn2+ ion at the B-site is 
more stable than that at the A-site, similar to other ligands observed in mAC crystal 
structures (Mou et al., 2005; Mou et al., 2006). 
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Figure 19. Crystal structure of Gs/FS-activated mAC with MANT-ITP and two Mn
2+
 ions in the catalytic 
site. MANT-ITP and two metal ions are bound in the cleft between the soluble domains C1a and C2a. The 
coloring scheme of figures A-D is: VC1 and IIC2 are colored wheat and violet, respectively. MANT-ITP is shown 
as stick model, carbon atoms are cyan, nitrogen atoms are darkblue, oxygen atoms are red, and phosphorus 
atoms are green. The two Mn
2+
 ions are shown as orange spheres. A, Difference electron density for 3´-O-
MANT-ITP and Mn
2+
.
 
The lime green wire represents the |Fo|-|Fc| electron density for MANT-ITP contoured at 2.5 
σ. The blue wire corresponds to the |Fo|-|Fc| electron density for the two Mn
2+
 ions contoured at 5 σ. The 
coordinates for the ligands were omitted from the phasing model. The secondary structure elements of the 
complex are labeled as defined previously (Tesmer et al., 1997). B, Detailed view of substrate-binding site of 
VC1:IIC2 with MANT-ITP:Mn
2+
. The catalytic site of VC1:IIC2 shows MANT-ITP, A- and B- site of two Mn
2+
 ions 
and the protein residues that are responsible for ligand interaction. The interaction among protein residues and 
MANT-ITP, Mn
2+
 are shown as gray dashed lines. C, Superimposed crystal structures of 3´-O-MANT-ITP and 
3´-O-MANT-GTP. The derived MANT-ITP crystal structure was superimposed and compared with the crystal 
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structure of MANT-GTP, shown as a transparent yellow stick model (Protein Data Bank code 1TL7) (Mou et al., 
2005). The protein residues are in almost identical conformation and the inhibitors are situated in the substrate- 
binding pocket in a similar fashion. D, Superimposed purine binding site of 3´-O-MANT-ITP and 3´-O-MANT-
GTP. The interaction of the hypoxanthine ring and guanine ring of MANT-ITP and MANT-GTP are shown as 
black and olive green dashed lines, respectively. The distances of hydrogen bond between the hypoxanthine ring 
and surrounding protein residues of MANT-ITP are indicated in Å. The hydrogen bond between I1019 and the 
amino group of MANT-GTP is missing in the MANT-ITP structure. K938 and the oxygen of the hypoxanthine ring 
are further apart (3.77 Å versus 3.4 Å). The hypoxanthine ring has less binding constraint in the purine binding 
pocket in comparison to the guanine ring of MANT-GTP. 
 
The structure was compared to the crystal structure of mAC with MANT-GTP for 
differences in binding mode because these two analogs are structurally very similar (Mou et 
al., 2005) (PDB code 1TL7). Superimposing both structures the overall placement of VC1 
and IIC2 did not differ greatly from each other with the RMSD less than 0.5 Å (Figure 19 C).  
The overall MANT-ITP conformation was similar to the MANT-GTP in the mAC structure 
having similar H-bond interactions as well as metal ion coordination with the protein residues 
(Figure 19 B and D). The |Fo|-|Fc| electron density map for MANT-ITP was well defined and 
showed clearly that there is no obvious conformational difference between the two ligands. 
Therefore we looked for minor differences in the very similar binding mode of MANT-ITP and 
MANT-GTP. One noticeable difference is that the hypoxanthine ring of MANT-ITP lacks an 
amino group that could form a hydrogen bond with the side chain of I1019 of IIC2-domain 
(MANT-GTP 2.6 Å; Figure 19 D). We checked if a conformational inversion of the 
hypoxanthine ring in the base binding pocket, which would lead to a stronger interaction with 
D1018 and W1020, could explain the higher affinity of MANT-ITP. However, this 
conformation was not favored by the ligand, because the ribose moiety was sterically 
hindered. The decreased interaction in the purine binding site for MANT-ITP would 
apparently lead to lower binding strength between the MANT-ITP and mAC protein. 
However, the observed difference in the purine binding pocket between MANT-ITP and 
MANT-GTP structures are contradictory because we observed a higher inhibitory potency of 
MANT-ITP on mAC compared to MANT-GTP (Table 2, 1.5.1.1).  
 
Thus, it appears that other interaction sites of MANT-ITP with the mAC are more 
important for the high affinity. The average temperature factor (B-factor) of the bound FS and 
GTPγS between these two structures is similar, but the B-factor of MANT-GTP is higher than 
that of MANT-ITP (the B-factor of MANT-GTP and MANT-ITP is 55 and 41, respectively), 
indicating a more restricted degree of freedom of MANT-ITP and a well predicted location of 
the molecule in the binding pocket. The high inhibitory potency of MANT-ITP may, therefore, 
be related to a more complicated binding energy distribution. The binding affinity of the 
MANT nucleotide is dependent on the three binding groups in the catalytic pocket – 
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interacting with base-binding site, phosphate-binding site and MANT-binding site. The lower 
binding constraint of MANT-ITP in the purine binding pocket could lead to a higher affinity of 
the molecule for the hydrophobic MANT-binding site and the phosphate binding site.  
The stronger hydrophobic interaction of MANT-ITP can be assessed by fluorescence 
spectroscopy, both basal direct fluorescence and FRET of MANT-ITP are increased at least 
50% compared to MANT-GTP. If we compare these results with another very similar MANT 
nucleotide, MANT-XTP, we see almost no increase in direct fluorescence or FRET (Figure 4, 
1.5.1.2). Compared to MANT-ITP and MANT-GTP, MANT-XTP is at least 60-fold less potent 
on VC1/IIC2 (Table 2, 1.5.1.1). It has oxygen on the C2-position of the purine ring that 
introduces a repulsion force on D1018 in the base-binding pocket and may move the MANT-
group away from the hydrophobic pocket, leading to strong decrease in inhibitory potency 
and fluorescence properties.  
 In the crystal structure the location of the 
MANT-group of MANT-ITP and MANT-GTP form 
similar interactions at the interface of 4‟-1-
domain. The aryl function of MANT has 
hydrophobic interaction with A409, L412, V413, 
V1024, V1026 and W1020. The oxygen of the 
carbonyl group of MANT-ITP moved in closer 
proximity to N1025 compared to MANT-GTP 
(Figure 20). Interestingly, this oxygen is very close 
to the carbonyl oxygen of the N1025 side chain 
(2.77 Å), introducing a repulsion force. A 180° 
rotation of the amide group of N1025 (NH2-C=O 
instead of O=C-NH2) would form much better 
interactions between the MANT-group and N1025 
(hydrogen bond between amino group of N1025 
and oxygen of MANT-ITP as well as with the 
carbonyl oxygen of G1021). We tried to reverse 
the obtained conformation to achieve H-bonding between MANT-ITP and N1025. However, 
after every round of refinement the amide of N1025 flipped back to its original, entropically 
favored location. The same event happened during Molecular Dynamics (MD) simulations. It 
has to be mentioned that the |Fo|-|Fc| electron density is not very strong for the MANT-moiety, 
suggesting that it is poorly ordered within the binding site (Figure 19 A).  
A stronger interaction of MANT-ITP with the phosphate binding site is supported by two 
observations. The side chain K1065 of IIC2 interacts with the β- and -phosphate of MANT-
ITP, whereas the amino group of K1065 in the MANT-GTP structure is only orientated 
 
 
Figure 20. MANT-binding site. The carbonyl 
group of MANT-ITP is in closer contact to 
N1025. Apart from that no conformational 
differences between MANT-ITP and MANT-GTP 
are detected. 
N1025 
I1019 
W1020 
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towards the -phosphate (Figure 19 C). The amino group of K1065 is also significantly closer 
to the oxygen of the β-phosphate of MANT-ITP (2.86 Å) in comparison to the oxygen of the -
phosphate of MANT-GTP (3.06 Å). However, we have to be careful about the interpretation 
of the interaction of the K1065 side chain with the phosphate group. Unfortunately, the 
resolution of the MANT-ITP structure is below 3 Å, and this can introduce errors in structure 
determination (up to +/-0.3 Å). Furthermore, the electron density of K1065 side chain was not 
well defined and we showed the energetically most favorable conformation after several 
rounds of structure refinements. It is, therefore, possible that the side chain does not differ as 
much as is expected by our model. MD simulations support the crystallographic data. During 
the 10 ps simulation the distance between the amino group of K1065 and the gamma 
phosphate is effectively identical with 3.04  0.11 Å and 3.05  0.12 Å for MANT-GTP and 
MANT-ITP, respectively. In contrast, the distance of the β-phosphate of MANT-ITP and 
K1065 (3.69  0.14 Å) is significantly smaller than for MANT-GTP (4.15  0.28 Å).   
 
Another interesting interaction in the phosphate binding site is visible between MANT-ITP 
phosphate groups and D396. On first glance, it looks contradictory that the carboxyl group of 
D396 does have closer interaction to the phosphate oxygen group of MANT-ITP (2.73 Å) in 
comparison to MANT-GTP (3.2 Å), introducing electrostatic repulsion. But this amino acid is 
also important to coordinate the two metal ions that are important for phosphate interaction 
with the protein residues of VC1 (D396, I397 and D440) (Figure 19 B). Due to the fact that 
D396 and MANT-ITP are in closer proximity to each other they introduce differences in metal 
coordination for MANT-ITP and MANT-GTP. With the different arrangement of the two metal 
ions to the phosphate groups we recognize that the Mn2+ ions in the MANT-ITP structure 
have more interaction with the - and -phosphate whereas in the MANT-GTP structure the 
Mn2+ ions seem to focus on the β-phosphate (Figure 21).  
 
It also appears that the gap between the phosphate groups and the important VC1-
residues is much smaller in the MANT-ITP structure, because there is also a closer proximity 
between I397 and the -phosphate of MANT-ITP (2.86 Å) in comparison to MANT-GTP 
(3.38 Å). The phosphate site plays a crucial role for binding affinity. This is further assessed 
by changes in potency due to differences in the phosphate moiety. As soon as a phosphate 
group is missing there is a strong decrease in potency; MANT-GTP has  70-fold higher 
affinity at VC1/IIC2 in comparison to MANT-GDP (Gille et al., 2004). Furthermore, affinities 
are influenced by substitution of oxygen for sulfur at the -phosphate. MANT-ITPS has a 
decreased potency at recombinant ACs in comparison to MANT-ITP, maybe because sulfur 
introduces a repulsion force. In contrast, MANT-GTPS and MANT-ATPS have a higher 
affinity in comparison to the corresponding MANT-NTPs (Table 2, 1.5.1.1). 
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Figure 21. Phosphate binding site of mAC. The graphic is based on the two 
crystal structures and shows the relative positions of K1065 and the kinking in 
the phosphate chain. Note that MANT-ITP is represented by thinner, darker 
sticks than MANT-GTP. The phosphate chain of MANT-GTP is more bended in 
comparison to MANT-ITP. The Mn
2+
 ions are shown as large spheres to 
illustrate the differences between MANT-GTP (light green spheres) and MANT-
ITP (dark green spheres). The Mn
2+
 ions of MANT-ITP are distributed between 
the phosphate groups.  
 
 
3.3. Discussion 
We have resolved the mAC crystal structure with the most potent competitive inhibitor 
known so far and assume that a balance of binding energies among the three 
pharmacophores in the mAC binding site considerably affects ligand potency. First of all, we 
could show that the MANT-ITP structure shares the common features with previously 
published mAC structures in complex with 2‟,3‟–substituted purine and pyrimidine nucleotide 
inhibitors, where the base, triphosphates and 2‟,3‟-ribose substituents reside in three distinct 
grooves of the substrate-binding site (Mou et al., 2006). The overall conformations of MANT-
ITP and MANT-GTP show minimal differences. This result is not surprising. The crystal 
structures were derived with a racemic mixture of 2‟-O- and 3‟-O-MANT-ITP. Both structures 
favor the 3‟-O-MANT-conformation for binding to the catalytic center as shown with the 
MANT-GTP crystal (Mou et al., 2005). The strong |Fo|-|Fc| electron density in the gap of 
N1025 and the 2‟-OH-group of MANT-ITP could indicate that it can also bear the 2‟-O-MANT 
isomer. However, the orientation of the other functional groups cannot be accommodated in 
Crystal structure of MANT-ITP mAC complex 
 60 
the experimental electron density with the same good quality. The better fit of the 3‟-O-MANT 
isomer is further explained by the better fit of the 2‟-OH group at the interface of IIC2.  
 
A very intriguing finding was the subtle difference in binding mode of MANT-ITP at the 
purine-binding site in comparison to the high inhibitory potency of the nucleotide. Usually, 
high inhibitory potency is accomplished through strong binding of the inhibitor to the active 
site of the enzyme. Hence, there have to be strong protein-ligand interactions. In our case, 
there was actually less protein-ligand interaction due to a missing hydrogen bond. 
Nonetheless, it was already shown in several publications that a gain in affinity is not only 
related to the number of hydrogen bonds, but also to hydrophobic interactions, residual 
mobility of the ligand and partial solvation of the binding pocket (Gohlke and Klebe, 2002). 
The loss of hydrogen bonds does not necessarily lead to a decrease in binding affinity of a 
ligand to a protein as assessed by molecular thermodynamic and crystallographic studies of 
thermolysin inhibitors (Morgan et al., 1991). Binding of those inhibitors is, therefore, not only 
dependent on hydrogen bonding, but also on metal coordination and higher ligand basicity 
(Grobelny et al., 1989). In the MANT-ITP structure, the loss of hydrogen bonding is negligible 
for an increase in affinity.  
Comparing three different MANT/TNP inhibitors and their structural variations in the 
binding pocket already revealed that hydrogen bonds to the base seem to have small 
contribution to interaction strength (Mou et al., 2006). SVD (Singular value decomposition) 
calculation was used to compare the contribution of the three different pharmacophores for 
inhibitory potency and it showed that the 2‟,3‟-ribosyl substituent contributes much more to 
inhibitory potency than the phosphate groups and the least contribution was made by the 
base variations (Figure 22). However, hypoxanthine substitution increases ligand affinity by 
10-fold compared to guanine substitution and improves interaction with the catalytic site as 
assessed by fluorescence spectroscopy. The base substitution plays a role in inhibitory 
potency, as soon as repulsion forces in the purine binding pocket lead to a strong decrease 
of the nucleotide potency which also affects hydrophobic interactions, as shown with MANT-
XTP (Figure 4, 1.5.1.2) and MANT-ATP (Mou et al., 2006). The fluorescence data support 
our hypothesis that between the various MANT nucleotides there are subtle differences in 
binding of the MANT-group to the hydrophobic pocket. If MANT-ITP is subjected to less 
binding constraints in the purine-binding pocket compared to MANT-GTP, it can better move 
into the hydrophobic regions of the MANT-binding site, which is associated with higher 
fluorescence signals.  
 
Besides of the strong hydrophobic interactions, MANT-ITP seems to bind more tightly into 
the phosphate binding pocket. The metal coordination of the phosphate groups in the 
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phosphate binding site of VC1 is very important for the high inhibitory potency of MANT-ITP. 
The relative electrostatic energies of the triphosphate - metal complex, ignoring all the other 
substituents (such as base, sugar, MANT-group) are almost identical for MANT-ITP and 
MANT-GTP with -254 kcal/mol and -253.9 kcal/mol, respectively. However, the bond/angle 
strain in the MANT-GTP β-phosphate is much higher (64.9 kcal/mol) than in the MANT-ITP 
one (49.5 kcal/mol). This indicates that the MANT-GTP phosphate groups are significantly 
kinked in comparison to MANT-ITP (Figure 21). The average temperature factor of MANT-
ITP:Mn2+ is lower than that of MANT-GTP:Mn2+ and also much lower than MANT-ATP and 
TNP-ATP:Mn2+, which indicates that MANT-ITP is much more ordered in the crystal structure 
than the other three ligands. It is also possible that the high B-values reflect only partial 
occupancy of the catalytic site of VC1:IIC2, especially by the latter two ligands (Mou et al., 
2005; Mou et al., 2006).  
 
 
 
 
 
 
 
Pharmacophore Component Ki* (µM) 
Base Adenine 2.9 
 Guanine 48.9 
 Cytidine 175 
 Uracil 110 
 Hypoxanthine 4.6 
 Xanthine 247,000 
Ribose substituent MANT (0.014  0.001) 
 TNP 0.003 
Phosphate Monophosphate 371,000 
 Diphosphate 443 
 Triphosphate 0.06 
 -Thio-triphosphate 0.45 
 
 
Figure 22. General pharmacophore model of 2’,3’-ribose-substituted mAC inhibitors. The model shows the 
three functional groups, nucleotide base (grey), phosphate group (green) and 2‟, 3‟-ribose substituent (blue). 
SVD analysis calculated overall Ki values that represent the contribution of each functional group (on the left 
side) and Ki* values (on the right side) that indicate the contribution of individual components (Mou et al., 2006).  
 
Finally, we compared the MANT-ITP crystal structure with the MANT-ATP crystal 
structure, PDB code 2GVZ. SVD analysis calculated a high contribution of the adenine 
group; hence MANT-ATP was first expected to be the most potent MANT nucleotide (Mou et 
al., 2006). However, exchange of hypoxanthine by adenine caused a decrease in potency by 
at least 60-fold (Table 2, 1.5.1.1). Superimposing both crystal structures showed that MANT-
ITP and MANT-ATP adopt the same conformation in the binding pocket between the C1:C2 
interface. However, one obvious difference is visible in the purine binding site: The 
hypoxanthine ring of 3‟-O-MANT-ITP adopts an anti conformation with respect to the ribosyl 
Ribose substituent 
Ki = 0.065 nM 
Phosphate 
Ki = 0.23 µM 
Base 
Ki = 26.4 µM 
Crystal structure of MANT-ITP mAC complex 
 62 
residue that allows interaction with K938 and D1018 (Figure 19 D and 23 A). Meanwhile, 
MANT-ATP does not form hydrogen bonds in the purine binding pocket and interacts with 
mAC by weak hydrophobic interactions (F889, L438 and I940). In contrast to MANT-ITP, the 
adenine ring is situated in the purine binding pocket in syn conformation and introduces 
electrostatic repulsion on D1018 leading to a strong decrease in potency (Figure 23 B).   
 
 
 
 
 
 
 
 
 
 
Figure 23. 3’-O-MANT-ITP versus 3’-O-MANT-ATP crystal structure (PDB 3G82 and 2GVZ). Coloring 
scheme of VC1, IIC2 and MANT-ITP adopted from Figure 19. MANT-ATP is shown as magenta stick model. 
Figure 22 B shows the anti and syn conformation of the purine rings of MANT-ITP and MANT-ATP, respectively 
and the important proteins residues within 3 Å that interact with the ligands.  
 
It should be mentioned that differences in inhibitory potency are not only restricted to 
direct protein-ligand interaction, but also to interaction with bound water molecules. 
Unfortunately, the resolutions of MANT-ITP and MANT-GTP crystal structures are not 
sensitive enough and, therefore, the detection of water molecules is poor. Another 
explanation for the higher inhibitory potency of MANT-ITP could be the possibility of another 
ligand conformation in the purine binding site that is not resolved with the obtained X-ray 
data.  
In conclusion, our data could corroborate the three-site pharmacophore model (Figure 22) 
already postulated in previous studies (Mou et al., 2005; Mou et al., 2006). The contribution 
for binding differences could be assessed with very accurate structural information of the 
complex, however, sometimes further evaluation of catalytic activity and fluorescence are 
necessary to understand contradictory binding affinities. 
F889 
A B 
D1018 
D1018 
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4. Effects of MANT nucleotides in cardiomyocytes 
4.1.  Cardiomyocyte preparation 
 The cardiomyocyte preparation is influenced by many parameters, like temperature of the 
Langendorff apparatus, composition of the solution and digestion with collagenases. 
Especially the collagenases (CLS) can vary in their activity as indicated in Table 4.  
 
 
Set 
 
Composition 
 
Batch 
 
CLS Activity 
(U/mg) 
 
Caseinase  
activ. (U/mg) 
 
Clostripain 
activ. (U/mg) 
 
Tryptic activ. 
(U/mg) 
Cell yield 
I 
Collagenase 1 
Collagenase 2 
X6C8693 
46H8900 
191 
200 
392 
545 
3.4 
4.3 
0.3 
0.3 
Good 
II 
Collagenase 1 
Collagenase 2 
S5K8219 
S9H11286 
230 
240 
350 
360 
2.31 
4.37 
0.35 
0.81 
NON 
III 
Collagenase 1 
Collagenase 2 
S9C11129 
S8P10943 
250 
360 
275 
560 
1.86 
4.23 
0.44 
0.67 
NON 
IV 
Collagenase 1 
Collagenase 2 
S5P8401 
M8B10274 
172 
210 
204 
440 
1.5 
4.0 
0.26 
0.22 
Good 
V 
Collagenase 1 
Collagenase 2 
S8B10327 
S8N10850 
210 
230 
370 
515 
2.2 
4.21 
0.18 
0.29 
FEW 
 
Table 4. Collagenase sampling. Because of lot-to-lot variations it was necessary to pre-test particular enzyme 
lots. Different collagenase batches were tested at least two times under equal assay conditions to select the best 
combination for cardiomyocyte preparation. Collagenase lots with a high tryptic activity showed only small cell 
yields or no living cell at all. 
 
We carefully examined the cardiomyocytes after digestion and used only freshly isolated 
cells for electrophysiological measurements that were rod-shaped and showed a clear 
striation as shown in the following figure (Figure 24).  
 
 
 
 
 
A B 
50 µm 10 µm 
MANT nucleotides in intact cells 
 64 
 
 
Figure 24. Cardiomyocyte micrographs. 
These pictured cardiomyocytes were taken 
for measurements. Micrograph A shows 
several cells in 200-fold magnification, B 
shows one single cardiomyocyte that has 
clear striation and a “log”-kind shape. C 
illustrates a cell shortly before seal 
formation. The light reflection from the 
pipette tip is clearly visible in the middle of 
the cell. Pictures taken with a DMC 510 
microscope camera. 
 
4.2. Effect of MANT nucleotides on basal L-type Ca2+ current 
It was already shown in cardiomyocytes that MANT-GTPS elicited an inhibitory effect on 
basal as well as isoprenaline-stimulated L-type Ca2+ current in murine cardiomyocytes of WT 
mice. Studies on AC 5-/- mice showed that inhibition of L-type Ca2+ current was indirectly 
accomplished mainly via AC 5, because lack of this AC isoform attenuated the 
cardiomyocyte effect (Rottländer et al., 2007). Therefore, we wished to study the effect of an 
even more potent AC inhibitor, MANT-ITP, in intact cardiomyocytes to support the previous 
findings. We used the same strain of WT mice (C57BL/6) to isolate the cardiomyocytes and 
we applied a very similar patch clamp protocol. The only difference was a different holding 
potential and the recovery time between single measurements was shorter. We started at a 
holding potential of -80 mV that was more physiological than the previously applied -60 mV 
holding potential (Rottländer et al., 2007). Furthermore, we measured every 3 s the ICa,L 
signal depolarized at +10 mV. The previous study applied every 10 s current measurements 
during the 15 min time interval. Additionally, I-V measurements were conducted every 2 min 
during one patch clamp measurement and not only at the beginning and at the end. The 15 
minute time interval was chosen because MANT-GTPS showed significant changes in ICa,L 
after  10 min. Due to the fact that good results were achieved with 1 µM MANT-GTPS, we 
kept the concentration for all the other tested MANT nucleotides at 1 µM for a direct 
comparison of the data. 
4.2.1. Basal L-type Ca2+ current 
 First of all, we measured basal ICa,L current of ventricular cardiomyocytes of WT mice to 
evaluate the influence of MANT nucleotides on basal current. During the first measurements 
of basal L-type Ca2+ current with and without MANT-ITP in the patch pipette, the old amplifier 
(Axopatch 200A) broke down and we had to build up a new setup (Axopatch 200B). Figure 
25 shows a comparison of basal ICa,L current data from the old and new setup. The difference 
C 
10 µm 
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between both traces was negligible. The summarized data of basal ICa,L current without any 
MANT nucleotide and with MANT-ITP are, therefore, a combination of data collection with 
the old and new setup. Data collection of MANT-ITPS, MANT-GTPS and MANT-ATP 
measurements was later achieved by using the new setup. 
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Figure 25. Control measurements with the old and new patch-clamp setup. The picture shows ICa,L current 
normalized to the capacitance of single cells as current density in pA/pF to eradicate any variability in cell size. 
Patch clamp measurements are illustrated with filled squares, when done with the old patch-clamp setup. Filled 
circles show the measurements with the new patch clamp setup. Differences in Ca
2+
 current density between the 
two patch clamp setups are not visible and demonstrate that current measurements are not influenced by those 
changes. S.E.M. is not illustrated in this graph, because of better visualization, but is shown in Figure 26 B. 
  
 Figures 25 and 26 B show that basal ICa,L current decreased during 15 min due to a “run-
down” effect of the cardiomyocyte that can not totally be eliminated, even though Mg-ATP 
and EGTA were added to the patch pipette (2.2.4.4). The basal “run-down” was quite 
pronounced, because after 15 min we had a reduction in ICa,L of 18.4 ± 3.3% (Figure 26 B). In 
the following chapters, the effects of MANT nucleotides added to the pipette solution are 
evaluated and compared to control.  
4.2.2. Effect of MANT-ITP in comparison to control 
 After addition of MANT-ITP to the pipette solution we observed within the first 2.5 min a 
current increase of basal Ca2+ current that was not detected in the control measurements 
(Figure 26). It seems that MANT-ITP immediately expressed an effect in cardiomyocytes that 
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was not correlated to the expected AC inhibition. After 2.5 min ICa,L current decreased to a 
higher extent compared to control. The inhibition of ICa,L current by MANT-ITP reached a 
steady-state level after  12 min, because Ca2+ current decrease approached current 
decrease of basal “run-down”. 
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Figure 26. Basal MANT-ITP (A) versus control measurements (B). Mean and S.E.M. of basal ICa,L current with 
MANT-ITP (n=8) or no inhibitor (n=10) in the patch pipette. Both graphs illustrate that measurements start at 
similar current densities (MANT-ITP = -5.67 ± 0.50 pA/pF versus control = -5.7 ± 0.35 pA/pF). During the first 
2.5 min, MANT-ITP showed a substantial current increase that was not visible without MANT nucleotide. 
Afterwards, a stronger decrease of basal ICa,L was detected with MANT-ITP in comparison to control experiments.  
 
4.2.3. Replication of MANT-GTPS experiments 
Due to the fact that we observed an initial current increase with MANT-ITP, we repeated 
the measurements with MANT-GTPS. On the one hand, we were specifically interested in 
reevaluation of the first 5 min, when MANT-GTPS is present in the patch pipette to verify if 
previous experiments with MANT-GTPS did not observe the initial current increase. On the 
other hand, we wanted to replicate the data obtained by Rottländer et al., because we 
already observed strong differences in basal ICa,L “run-down” (Rottländer et al., 2007). 
Figure 27 shows a continuous reduction of ICa,L by MANT-GTPS over the 15 min time 
course, but the current inhibition was much smaller compared to MANT-ITP (Figure 26 A). At 
the beginning a slight current increase could be detected that is not significantly different, 
compared to control. Thus, it could be verified that MANT-GTPS does not exhibit a 
characteristic stimulating effect on L-type Ca2+ channels. This was also confirmed by 
evaluation of the I-V relationship during the 15 min run, because we could not observe a 
strong difference in peak current at +10 mV during the first 2.5 min and the I-V curve did not 
express a horizontal shift over time (Figure 27 B). Furthermore, after 15 min ICa,L was 
A B 
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decreased by 38.9 ± 5.3%, which is comparable to the already published data. Again, we 
observed that the MANT-GTPS effect reaches steady-state levels after  12 min.  
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Figure 27. Basal MANT-GTPS experiments. A, Mean and S.E.M. of basal ICa,L current with MANT-GTPS 
(n=10) and B, I-V relationship of MANT-GTPS over time. An initial current density increase with MANT-GTPS 
was not detected. The highest current density was accomplished with a test pulse of +10 mV, affirming the 
detection of L-type Ca
2+
 current. The current-voltage curve did not show a horizontal shift, suggesting that the 
MANT nucleotide did not directly affect Ca
2+ 
channel phosphorylation. 
 
4.2.4. Effect of MANT-ITPS  
 MANT-ITP and MANT-ITPS showed very similar inhibition on AC, especially on cardiac 
AC membrane preparations (1.5.1.1). Therefore, we applied the hydrolysis resistant analog 
of MANT-ITP, to evaluate the stability of MANT-ITP in intact cells. Interestingly, we detected 
an even higher current increase with MANT-ITPS compared to MANT-ITP and this effect 
started immediately after the beginning of the WC measurement, because the first current 
density measurement after  0.5 min (-9.19 ± 0.8 pA/pF) showed already higher values than 
MANT-ITP or control (-5.67 ± 0.50 pA/pF and -5.7 ± 0.35 pA/pF, respectively). The current 
density increased to -11.75 ± 0.4 pA/pF within the first 2.5 min (+106% increase compared to 
control). Figure 28 A illustrates five single WC measurements that reflect the significant initial 
current increase. The experiments were performed on several independent days. Therefore, 
we can exclude the possibility that the effects are related to the cardiomyocyte preparation. 
This must be also applied to the current decrease that starts after  2.5 min. Two of five 
experiments showed a more pronounced current decrease than the other 3 experiments 
(MIS1 and MIS4). However, they are obtained from different cardiomyocyte preparations 
and the slope of the curves decreased to the same extent. Due to the fact that no difference 
A B 
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in the accomplishment of the patch was detected for any of the 5 experiments, we combined 
all the measurements with each other.   
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Figure 28. Single experiments (A) and I-V curves (B) of MANT-ITPS (MIS). The five single WC 
measurements (MIS 1-5) show clearly that there was a pronounced current increase at the beginning that 
exceeded MANT-ITP effects. Two of the five experiments showed a stronger current decrease (MIS 1 and 4), 
but the inhibition was to a similar extent. Therefore all of the five experiments were taken for evaluation. I-V 
curves show clearly the current increase during the first 2.5 min, but no horizontal peak shift. 
 
4.2.5. Effect of MANT-ATP 
Based on the contradictory findings of stimulating effects with MANT-ITP and MANT-
ITPS we also investigated the effects of MANT-ATP on cardiomyocytes. MANT-ATP inhibits 
AC 5 with 200-fold lower potency than MANT-ITP (Ki 200 nM). Therefore, we expected no 
significant effect of MANT-ATP on basal ICa,L (“negative control”). However, in contrast, we 
found an even larger initial current increase than with MANT-ITP and the subsequent current 
decrease was comparable to MANT-ITP (Figure 29). Again, basal ICa,L current density 
reached a steady-state plateau after  13 min. 
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Figure 29. Basal effect of MANT-ATP 
on cardiomyocytes.  
Mean and S.E.M. of basal ICa,L current 
density with MANT-ATP (n=6). MANT-
ATP showed an initial current increase 
that exceeded MANT-ITP effects. After 
2.5 min Ca
2+
 current is inhibited by 
MANT-ATP. The inhibitory MANT-ATP 
effect vanished after  13 min. 
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4.2.6. Comparison of MANT nucleotides 
Figure 30 shows single original traces of basal L-type Ca2+ current and the effect of 
different MANT nucleotides. As expected, basal ICa,L decreased during the 15 min time 
interval triggered by a “run-down” of the cell (Figure 30 A). The ICa,L peak was at the 
beginning higher when MANT-ITPS and MANT-ATP were present in the patch pipette, 
compared to control (Figure 30 C and E). Furthermore, we observed a more pronounced 
decrease of ICa,L with these two nucleotides, but the overall inhibition of ICa,L was not very 
large, because it reached only basal current levels after 15 min. The ICa,L peak of MANT-ITP 
was also higher than control, but not as pronounced as for the other two nucleotides (Figure 
30 B). MANT-GTPS did not show an increased peak current, but the ICa,L peak at the end 
was smaller than control (Figure 30 D).  
  
  
 
 
Figure 30. Original traces of L-type Ca
2+
 current in 
the absence (A) and presence (B, C, D and E) of 
MANT nucleotide (1 µM).  
Starting from a holding potential of -80 mV, a prepulse 
of -40 mV for 45 ms was administered, followed by a 
test potential of +10 mV. The ICa,L peak was detected 
at  60 ms and decreased during 15 min with A no 
drug present, B with 1µM MANT-ITP, C with 1µM 
MANT-ITPS, D with 1µM MANT-GTPS and E with 
1µM MANT-ATP in the pipette.  
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To summarize the effects of MANT nucleotides over the 15 min time interval, Figure 31 
incorporates all measurements taken at +10 mV with the two pulse protocols. The time 
course is now averaged to specific time points to superimpose and better illustrate single I-V 
measurements and peak ICa,L current measurements.  
 
Figure 31 illustrates that MANT-ITP and control experiments start at the same ICa,L current 
density, but MANT-ITP current density increased during the first 2.5 min to a higher extent 
than control. During the subsequent decrease it exceeded the “run-down” of control 
experiments, but not to a very large extent. In contrast, MANT-ITPS and also MANT-ATP 
showed a very pronounced current increase at the beginning that started immediately and 
thus suggests that the diffusion of the MANT nucleotide was achieved within the first 30 
seconds. MANT-ITPS was able to inhibit ICa,L after the initial current increase and the 
inhibition was much stronger compared to control, but the overall effect after 15 min did not 
exceed the basal “run-down”. MANT-ATP did not show such a strong current increase as 
MANT-ITPS and also expressed a current inhibition after 2.5 min. Therefore ICa,L is 
decreased after 15 min, exceeding control measurements and interestingly, the overall effect 
was similar to MANT-ITP. MANT-GTPS started at a smaller ICa,L current density than control 
experiments, but the difference was not significant (-4.5 ± 0.4 versus -5.7 ± 0.4 pA/pF, 
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Figure 31. Effect of MANT nucleotides (1 µM) on basal L-type Ca
2+
 current in WT cardiomyocytes.  
Averaged time course of whole cell L-type Ca
2+
 current density in the absence and in the presence of MANT 
nucleotide (1 µM). Note that only in the presence of MANT-ITPS, MANT-ITP and MANT-ATP we observed an 
initial current increase.  
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respectively) and might be related to an instantaneous current inhibition. The ICa,L current 
density values for MANT-GTPS resembled already published data and also showed a lower 
starting point for MANT-GTPS (Rottländer et al., 2007). MANT-GTPS did not show the 
initial current increase and the current inhibition did not approach the inhibitory effects seen 
with the other MANT nucleotides. However, the overall effect might be even higher than for 
the other MANT nucleotides, because ICa,L current density was much lower for MANT-GTPS 
compared to control experiments and the other MANT nucleotides after 15 min. Table 5 
provides a statistical summary of all these findings. 
 
 
Parameters 
 
Control 
 
 
MANT-ITP 
 
MANT-ITPS 
 
MANT-GTPS 
 
MANT-ATP 
 
Initial current 
increase (%)
1 
 
13.9 ± 2.9 28.75 ± 8.2 
106.2 ± 7.02 
***
, +++, ### 18.6 ± 4.6
(a) 
48.2 ± 8.3**
, # 
 
Relative current 
decrease (%)
1 
 
18.4 ± 3.3 30.8 ± 7.8 8.34 ± 16.8
# 
43.2 ± 5* 27.1 ± 2.2 
 
Inhibition based 
on max. ICa,L (%)
 
 
28.0 ± 3.4 49.2 ± 3.5** 54.5 ± 9.2** 38.9 ± 5.3* 47.1 ± 5* 
 
ICa,L current 
density (pA/pF) 
at beginning  
 
-5.7 ± 0.4 -5.67 ± 0.5 
-9.2 ± 0.8 
***
, +++, ###
 
-4.5 ± 0.4 -6.4 ± 0.5 
 
Maximum ICa,L 
current density 
(pA/pF)
 
 
-6.5 ± 0.4 -7.34 ± 0.5
# -11.75 ± 0.4 
***
, +++, ###
 
-5.3 ± 0.4 -8.45 ± 0.5*
,### 
 
n 
 
10 8 5 10 6 
 
Table 5. Summary of WC experiments with and without MANT nucleotides. Mean and S.E.M. of initial current 
increase, current decrease and current densities at beginning and after  2.5 min of n experiments. After 15 min 
MANT-ITPS did not achieve a current inhibition, compared to control, due to a strong initial current increase. 
Overall, MANT-GTPS showed the highest current decrease compared to control, but the other MANT 
nucleotides showed stronger inhibitory effects after the initial current increase. 
1
 Values based on first control measurement, with no MANT nucleotide in the patch pipette. 
a
 Value is based on first WC measurement of MANT-GTPS, because current density at beginning was smaller 
than control. 
The results were compared using one-way ANOVA, followed by Bonferroni‟s/Dunnett‟s multiple comparison tests. 
Parameters are significantly different to: *control, 
+
MANT-ITP and 
#
MANT-GTPS. One symbol: p < 0.05; two 
symbols: p < 0.01; three symbols: p < 0.001; confidence interval 95%.
 
 
 Comparison of the cardiomyocyte effects with the inhibitory profile of MANT nucleotides 
on AC membrane preparations (ACs 1, 2, 5, 6 and cardiac AC) clearly revealed that the 
obtained current decrease was not correlated to AC inhibition (Table 2; 1.5.1.1, Table 5, 
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Figure 32 B). MANT-ATP possesses a 200-fold lower potency than MANT-ITP in AC 5 
membrane preparations, but the overall decrease of ICa,L current was not significantly 
different. Additionally, current decrease based on maximum ICa,L current density was also 
comparable for both AC inhibitors. Furthermore, MANT-GTPS effects should be lower 
compared to MANT-ITP and MANT-ITPS, because it is a less potent AC inhibitor on cardiac 
and AC 5 membrane preparations under Mg2+ conditions. This could be detected for the 
subsequent current decrease after 2.5 min, because the slope of current inhibition was 
steeper for MANT-ITP and MANT-ITPS. However, overall current inhibition was much 
smaller for MANT-ITPS and also less pronounced for MANT-ITP, due to the initial current 
increase.  
 The current increase was not related to AC inhibition. MANT-ITP, MANT-ATP and MANT-
ITPS expressed a strong current increase, even though they should be inhibitors on ICa,L 
current, due to their strong inhibitory potency on cardiac ACs. This stimulating effect on ICa,L 
was, therefore, not initiated via AC, but may be due to activation of another nucleotide 
binding protein that phosphorylates the L-type Ca2+ channel. An initial activation of AC that 
may increase ICa,L current can be also excluded, because, on the one hand we did not see a 
correlation between the affinity of MANT nucleotides for cardiac AC in membrane 
preparations and the indirect stimulating effects on L-type Ca2+ channels (Figure 32 A). On 
the other hand, AC activity assays with MANT nucleotides were carried out for 1-2 min, i.e. in 
the time of current increase and showed clearly AC inhibition in this time frame.  
100 1000 10000
-14
-12
-10
-8
-6
-4
-2
0
Ki cardiac membrane (nM)
m
a
x
im
u
m
 I
C
a
,L
 c
u
rr
e
n
t
d
e
n
s
it
y
 (
p
A
/p
F
)
 
Figure 32. Correlations of WC patch clamp 
effect with inhibitory AC-activity. 
A. Maximum ICa,L density in intact cells versus 
inhibitory affinity (Ki) on cardiac mice membrane 
preparations did not show that the detected 
effects are correlated to AC inhibition, because 
MANT-ATP showed stronger current increase 
than MANT-ITP and MANT-GTPS and MANT-
ITPS showed larger effects than MANT-ITP.  
B. Absolute current inhibition of MANT 
nucleotides versus Ki on cardiac AC. We 
observed a stronger inhibition after initial current 
increase with MANT-ATP compared to MANT-
GTPS and the effect was similar to MANT-ITP, 
although MANT-GTPS and MANT-ITP are 
more potent than MANT-ATP. Figure legend:   
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To evaluate if the MANT nucleotides have a direct effect on L-type Ca2+ channels we 
measured the current-voltage (I-V) relationship of all MANT nucleotides during the WC 
experiment. Isoproterenol, a β-AR agonist, enhances ICa,L and induces a shift of the I-V curve 
by about 10 mV toward more negative potential, because it indirectly activates AC via Gs 
and increases the phosphorylation of the Ca2+ channel via PKA. This leftward shift can be 
also detected with FS, a direct AC activator. Interestingly, we did not detect any leftward shift 
of the I-V curve during the whole experiment, even though we observed a current increase 
(Figure 33). This finding further strengthens our hypothesis that current increase is not 
elicited by AC. The following I-V curves show the current increase of MANT-ITP, MANT-ATP 
and MANT-ITPS during the first 2.5 min. The subsequent decrease thereafter lead to a 
slight inhibitory effect of MANT-ITP and MANT-ATP after 15 min, but MANT-ITPS did not 
exceed “run-down” levels of control. 
 
Figure 33. Current-Voltage (I-V) curves of basal L-type Ca
2+
 current at the beginning (A), at the largest 
current density (B) and at the end (C, t = 15min) of the experiment. The mean values of at least 5 
independent experiments with or without MANT nucleotide are shown. MANT nucleotides did not cause a voltage 
shift of the I-V curve. 
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4.3. Discussion 
 We characterized a class of potent AC inhibitors – MANT nucleotides – for their indirect 
effect and potency on basal L-type Ca2+ current in cardiomyocytes. We could confirm that 
MANT nucleotides influence the constant basal ICa,L. However, in contrast to previous 
experiments, MANT nucleotides show not only inhibitory effects on ICa,L, but have 
inconsistent impact on L-type Ca2+ channel activity. Until now, all the data about potency and 
selectivity of MANT nucleotides was gained in recombinant AC membrane preparations, 
providing information about direct AC inhibition by these nucleotides. However, we did not 
have data about the effects of MANT nucleotides in intact cells. Only one MANT nucleotide, 
MANT-GTPS, was subsequently tested in WC patch clamp experiments. It showed 
inhibition of Ca2+ current in cardiomyocytes via AC, with a strong impact on AC 5, because 
the inhibitory effect of MANT-GTPS was reduced in cardiomyocytes of AC 5-/- mice 
(Rottländer et al., 2007). Therefore, we expected that even higher inhibitory effects on basal 
ICa,L can be detected with more potent MANT nucleotides. Due to the fact that MANT-ITP as 
well as MANT-ITPS did not show a more pronounced current inhibition and meanwhile even 
increased ICa,L, we expect that the initial increase and subsequent decrease of basal ICa,L may 
be related to unspecific interactions of MANT nucleotides with other proteins or other AC 
isoforms that were not extensively monitored yet. The physiological role of other AC isoforms 
in heart such as 2, 3, 4, 7 and 9 is not clarified until now (Okumura et al., 2009). However, it 
is possible that the entity of ACs have an important influence on basal ICa,L. The MANT 
nucleotides used in our experiments were not tested on the other AC isoforms apart from AC 
2. It is possible that those MANT nucleotides might also express a diverse, relevant effect on 
ACs 3, 4, 7 and 9 and that the effect superimposes the inhibition of ACs 2 and 5.   
 
Most probably, however, is the possibility that MANT nucleotides undergo many 
intracellular interactions in cardiomyocytes. The intracellular signaling cascade is very 
complex and an appreciation of all protein interrelations with MANT nucleotides is currently 
missing. GPCRs, G proteins, mACs, phosphodiesterases, adenylate kinases and protein 
kinases influence the cAMP levels that regulate L-type Ca2+ channel activity. An unspecific 
effect of MANT nucleotides in this complex signaling cascade may not be eradicated by our 
findings. Studies with ANT- and MANT-ATP showed substrate activity for adenylate kinase, 
guanylate kinase, glutamine synthetase, myosin ATPase and Na+/K+-ATPase. MANT- and 
ANT-ADP are substrates for creatine kinase and the GMP- and adenosine derivatives are 
substrates for guanylate kinase and adenosine deaminase, respectively. On adenylate 
kinase, MANT-ATP showed the same Km values as ATP and even higher affinity for 
guanylate kinase (Hiratsuka, 1983). Many of these enzymes regulate ATP synthesis and 
hydrolysis. It is, therefore, possible that the MANT nucleotides change the physiological ATP 
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homeostasis by competition for the substrate-binding site of ATP binding proteins and that 
these effects lead to an initial increase in cAMP and ICa,L before AC inhibition is achieved.        
Especially the effects detected with MANT-ATP support the hypothesis that many other 
nucleotide binding proteins can use MANT-ATP and probably other MANT-NTPs instead of 
ATP as substrate (Figure 32). In one study, MANT-ATP, -ADP and the two deoxy substances 
MANT-2‟deoxy-ATP and MANT 3‟deoxy-ATP were tested for their affinity to the catalytic 
subunit of PKA (Ni et al., 2000). Binding to PKA was assessed by fluorescence resonance 
energy transfer, showing a large increase in FRET at 440 nm. Reversed-phase 
chromatography was used to measure PKA-induced phosphorylation of a small peptide 
substrate. It was found that MANT-ATP served as a phosphorylating agent in this PKA-
catalyzed reaction and both isomers of MANT-ATP are substrates for PKA. The rate for 
peptide phosphorylation is  20-fold lower than that for ATP. Additionally, MANT-GTPS and 
MANT-GppNHp are also known as inhibitors of G proteins and showed relatively high affinity 
and changes in fluorescence upon G protein binding (Remmers and Neubig, 1996; 
Remmers, 1998). The affinity of MANT-GTPS to recombinant Gs/Gi fusion proteins with 
the formyl peptide receptor or the β2-adrenergic receptor was 30- to 300-fold lower compared 
to GTPS (Gille and Seifert, 2003a). The stronger relative inhibition of ICa,L with MANT-
GTPS in comparison with the other MANT nucleotides could therefore be explained by a 
combined inhibition of both, AC and Gs. 
Another explanation for the diverse effects of the different MANT nucleotides could be that 
they interact not only with proteins of the AC pathway, but also via the cGMP-mediated 
pathway. Cardiac L-type Ca2+ current can be modulated by cGMP via activation of cGMP-
dependent protein kinase or regulation of cGMP-inhibited and activated cAMP 
phosphodiesterases (Lohmann et al., 1991). In frog ventricular cardiomyocytes, it was 
reported that cGMP can decrease isoprenaline- or cAMP-stimulated ICa,L by stimulation of 
cyclic nucleotide phosphodiesterases that increase cAMP hydrolysis (Hartzell and 
Fischmeister, 1986). Furthermore, in mammalian cells cGMP potentiates the stimulation of 
ICa,L by isoprenaline via cGMP-inhibited phosphodiesterases (Ono and Trautwein, 1991). Just 
recently, it was published, that MANT-GTP can also be a substrate and fluorescent probe for 
the detection of soluble guanylyl cyclase (sGC) activity. Stimulation of sGC with NO lead to a 
complete conversion of MANT-GTP to MANT-cGMP, confirmed by HPLC and fluorescence 
measurements. The Km of sGC for MANT-GTP was 35.7  9.37 µM and showed a similar 
enzyme affinity as the physiological substrate GTP (Newton et al., 2010). However, another 
study rather expects an enzyme inhibition. MANT-ATP and MANT-GTP showed effectual 
inhibitory potency on sGC with a Ki of 430 and 710 nM, respectively (Gille et al., 2004). The 
effects of MANT nucleotides on sGC are, therefore, quite controversial. MANT-cGMP was 
also tested on rabbit brain phosphodiesterase and showed substrate affinity. Interestingly, it 
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exhibits similar kinetic parameters than cGMP (Johnson et al., 1987). Therefore, interaction 
of MANT nucleotides with regulators of cGMP homeostasis could be also responsible for the 
complex electrophysiological results. 
 
MANT nucleotides directly enter the cell through the pipette solution. It was expected that 
intracellular dialysis requires some time. However, our findings showed that there is an 
immediate reaction, because MANT-ITPS showed right from the beginning a very strong 
ICa,L signal that is significantly different from control and other MANT nucleotides and is not 
related to any changes in the WC setup or cardiomyocyte preparation. Already published 
results with MANT-GTPS confirm that the intracellular dialysis is achieved in a short time, 
because MANT-GTPS expresses the strongest effect within the first 5 min and ICa,L 
decreases immediately to a higher extent than control (Rottländer et al., 2007). A steady-
state level is reached after  10 min and is compliant to the inhibitory profile of MANT-ITP, 
MANT-ITPS and MANT-ATP that reach steady state levels after  12-13 min.  
Comparison of our data with previous studies show that basal “run-down” after 10 min is 
increased with  13% versus  8%, respectively. This can be explained by differences in the 
patch clamp protocols, because in our protocol the cardiomyocytes are more stressed by a 
higher, but more physiological, holding potential of -80 mV versus -60 mV and by a 3-fold 
higher rate of WC measurements during the same time interval. In contrast, MANT-GTPS 
did not show a more tremendous reduction of ICa,L. Rottländer et al. already detected a 
reduction of ICa,L by 39.5  6.8% after 10 min. Anyway, the results are comparable, because 
we detected a reduction by 38.9 ± 5.3% after 15 min, but ICa,L decreases constantly, whereas 
in the previous study it reached steady-state levels after 10 min and reduction was not further 
enhanced anymore. 
  
We also evaluated the stability of MANT-NTPs versus MANT-NTPS. The differences in 
initial current increase and subsequent current decrease between MANT-ITP and MANT-
ITPS suggest that the hydrolysis-resistant MANT nucleotides are more stable (Figure 32 A, 
Table 5). This may be the fact, if these findings are correlated to the inhibitory potency on 
mAC, because MANT-ITP and MANT-ITPS show comparable affinity for cardiac AC. 
Therefore, we would have expected similar effects. However, the overall inhibitory effect for 
MANT-ITP after 15 min was still stronger than for MANT-ITPS, when compared to control. 
Furthermore, MANT-ATP also shows a continuous and strong decrease during the 15 min, 
although it is a less potent AC inhibitor and should also immediately hydrolyze. It has to be 
considered that the MANT-NTPs are also enzyme substrates. HPLC analysis of 5 µM MANT-
GTP and 8 µM MANT-cGMP showed that substrate conversion starts immediately, but a 
complete turnover is achieved after 1h with sGC and phosphodiesterase of rabbit brain 
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(Johnson et al., 1987; Newton et al., 2010). Therefore, a clear assertion about the nucleotide 
stability in cardiomyocytes is not possible and further investigation with other MANT-NTPs 
(e.g. MANT-GTP) and MANT-NTPS (e.g. MANT-ATPS) or investigations of the degradation 
products via HPLC analysis are necessary to clarify the stability of those nucleotides in cell 
assays.  
 
 During the patch-clamp experiment, all the tested MANT nucleotides did not change cell 
viability monitored by visual observation. This is in agreement with previous measurements 
and indicates that the MANT nucleotides do not express a toxic intracellular effect. 
 
In summary, the effects of MANT nucleotides on cardiomyocytes did not reflect the 
inhibitory profile obtained in recombinant and cardiac membrane preparations. Due to the 
fact, that a broad range of different MANT nucleotides were examined for their effects in 
intact cells and showed quite contradictory results, we observed that MANT nucleotides may 
influence a variety of proteins beside ACs and therefore, their selectivity for AC is quite 
equivocal. MANT nucleotides are suitable experimental tools for the analysis of recombinant 
ACs, purified catalytic mAC subunits and ACs in native cell membranes (Gille et al., 2004; 
Göttle et al., 2009; Pinto et al., 2009). They can also be effectively used as fluorescence 
probes and ligands for crystallography (Remmers, 1998; Mou et al., 2006). Unfortunately, 
MANT nucleotides also have various disadvantages. Due to their nucleotide structure, they 
have very poor membrane permeability and, hence, have to be injected into cells, limiting the 
type and number of experiments that can be conducted. Moreover, MANT nucleotides may 
bind to various nucleotide-binding proteins. The search for even more potent and selective 
non-nucleotidic mAC inhibitors that display higher membrane permeability may be 
established from our findings. A substantial advantage for the achievement of this ambitious 
goal is the fact that the substrate-binding pocket of AC is very flexible and can accommodate 
a broad range of inhibitors (Dessauer et al., 1999; Mou et al., 2006)  
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5. Summary 
Adenylyl cyclases (ACs) play a crucial role in G protein-coupled receptor signaling, 
because they generate cyclic adenosine 3‟,5‟-monophosphate (cAMP). AC inhibitors could 
be applied when pathophysiological high cAMP concentrations are predominant, such as in 
heart failure or neurodegenerative disorders. 2‟,3‟-O-(N-Methylanthraniloyl)-nucleoside 5‟-
triphosphates (MANT-NTPs) are a new class of potent AC inhibitors with isoform selectivity 
for ACs 1, 5 and 6 in comparison to AC 2 and MANT-inosine-5„-triphosphat (MANT-ITP) is 
currently the most potent known AC inhibitor. The present work is, on the one hand, about 
the molecular interaction of MANT-ITP with the catalytic subdomains of membranous AC 
(mAC) to understand the structure-activity relationship of MANT-NTPs with the enzyme. On 
the other hand, the effect of different MANT-NTPs in murine cardiomyocytes was analyzed. 
  
With the help of the crystal structure of MANT-ITP in complex with the VC1/IIC2-domains 
of mAC we could demonstrate that MANT-ITP has an almost identical conformation as 
MANT-GTP, when both crystal structures are superimposed. Based on a missing NH2-group 
in the hypoxanthine ring of MANT-ITP the structure does not provide a hydrogen bond to 
I1019. The apparent decrease in affinity at the purine binding site is more than compensated 
by an increased interaction with the hydrophobic MANT-binding site, as assessed by 
fluorescence measurements that show already under basal conditions an intensified direct 
fluorescence and an increase in fluorescence resonance energy transfer (FRET). 
Additionally, the MANT-ITP structure shows a better triphosphate-metal ion coordination and 
stronger interaction with K1065 in the phosphate-binding site which was confirmed with MD 
simulations. The binding affinity of MANT nucleotides for mAC is regulated via a balance 
between the purine-, MANT- and phosphate binding site and corroborates a previously made 
3-site-pharmacophore model.  
 
AC 5 knockout (AC 5-/-) mice exhibited cardioprotective effects in a pressure-overload 
model, and cardiomyocytes were protected against apoptosis. Therefore, MANT nucleotides 
as potent AC inhibitors with a high selectivity for AC 5, such as MANT-ITP, MANT-ITPS, 
and MANT-GTPS were examined in ventricular wildtype (C57Bl/6) cardiomyocytes. MANT-
ATP was used as a negative control, because it possesses a 200-fold lower affinity for AC 5. 
The substances were applied intracellularly and the indirect influence of ACs on L-type Ca2+ 
current (ICa,L) was detected via electrophysiological WC measurements. The effects of the 
MANT nucleotides on ICa,L were unexpectedly complex. MANT-ITP, MANT-ATP und MANT-
ITPS showed an initial current increase of  30, 106 and 48%, respectively, followed by a 
decrease of ICa,L after  2.5 minutes. The characteristics of MANT-GTPS are very similar to 
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control and consistent with already published data. All MANT-NTPs show an inhibitory effect 
on basal ICa,L, but the overall inhibition in comparison to control is low or not existent, 
because of the initial current increase. An explanation could be that MANT-NTPs 
activate/inhibit other target proteins beside the AC inhibition.  
 
Due to the complex, dually stimulatory and inhibitory effects in intact cells, the use of 
MANT nucleotides should be restricted as valuable fluorescent probes, crystallographic 
ligands and enzyme inhibitors to analyze recombinant and/or purified nucleotide-binding 
proteins. Hopefully, new inhibitors will exhibit greater selectivity for AC 5 and also membrane 
permeability. 
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6. Zusammenfassung 
Adenylylzyklasen (ACs) spielen in der G-Protein-gekoppelten Rezeptor-Signalkaskade 
eine entscheidende Rolle, weil sie einen wichtigen intrazellulären Botenstoff, zyklisches 
Adenosinmonophosphat (cAMP), synthetisieren. AC-Inhibitoren könnten pharmako-
therapeutisch bei pathophysiologisch erhöhten cAMP-Konzentrationen eingesetzt werden, 
die bei Herzinsuffizienz, aber auch bei neurodegenerativen Erkrankungen vorkommen. 2‟,3‟-
O-(N-Methylanthraniloyl)- (MANT-) Nukleotide stellen eine Klasse von AC-Inhibitoren dar, die 
eine Selektivität für ACs 1, 5 und 6 gegenüber AC 2 aufweisen. MANT-Inosin-5„-triphosphat 
(MANT-ITP) ist der potenteste Wirkstoff dieser Klasse. Die vorliegende Arbeit beschäftigt 
sich einerseits mit der molekularen Interaktion von MANT-ITP mit den aktivierten 
katalytischen Untereinheiten der membranären AC (mAC), um die Struktur-
Wirkungsbeziehung von MANT-Nukleotiden besser zu verstehen. Andererseits wurde die 
Wirkung verschiedener MANT-Nukleotide in intakten Kardiomyozyten der Maus analysiert. 
 
Anhand der Kristallstruktur von MANT-ITP im Komplex mit der VC1/IIC2 Untereinheit von 
mAC konnte gezeigt werden, daß MANT-ITP eine fast identische Konformation wie MANT-
GTP aufweist, wenn beide Kristallstrukturen übereinandergelegt werden. Aufgrund einer 
fehlenden NH2-Gruppe im Hypoxanthinring von MANT-ITP wird eine Wasserstoff-
brückenbindung zu I1019 nicht ausgebildet. Die scheinbare Affinitätsminderung in der 
Purinbindungstasche wird durch eine verstärkte Interaktion mit der hydrophoben MANT-
Bindungstasche mehr als ausgeglichen. Fluoreszenzmessungen bestätigten, dass sowohl 
die direkte Fluoreszenz als auch der Fluoreszenzresonanz-Energietransfer (FRET) mit 
MANT-ITP aufgrund der hydrophoben Wechselwirkung unter basalen Bedingungen erhöht 
sind. Außerdem zeigte die MANT-ITP-Struktur eine verbesserte Phosphat-Metallionen-
Koordination und eine verstärkte Interaktion mit K1065 in der Phosphat-Bindungstasche, was 
durch MD-Simulationen bestätigt wurde. Die Bindungsaffinität von MANT-Nukleotiden für 
mAC wird durch ein Gleichgewicht zwischen Purin-, MANT- und Phosphat-Bindungstasche 
hervorgerufen und bestätigt ein bereits bestehendes trimeres Pharmakophor-Modell. 
 
In AC 5 Knockout-Mäusen zeigte sich, dass das Fehlen der AC 5 eine kardioprotektive 
Wirkung im druckbelasteten Herzen hat und Apoptoseprozesse in Kardiomyozyten 
verhindert werden. Da MANT-Nukleotide potente AC-Inhibitoren sind und bereits gezeigt 
wurde, dass sie eine gewisse Selektivität für AC 5 aufweisen, wurden ausgewählte 
Substanzen (MANT-ITP, MANT-ITPS und MANT-GTPS) in ventrikulären Kardiomyozyten 
von C57Bl/6-Mäusen untersucht. MANT-ATP wurde aufgrund seiner 200-fach geringeren 
Affinität für AC 5 als Negativkontrolle eingesetzt. Dabei wurden die Substanzen anhand 
elektrophysiologischer Ganzzellmessung direkt intrazellulär appliziert und der indirekte 
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Einfluss von ACs auf den L-Typ Calciumkanalstrom (ICa,L) in Herzmuskelzellen von Mäusen 
vermessen. Die MANT-Nukleotide zeigten sehr komplexe Wirkungen auf ICa,L. MANT-ITP, 
MANT-ATP und MANT-ITPS zeigten einen ungewöhnlichen initialen Stromanstieg von 
jeweils  30, 106 und 48% bevor nach  2,5 Minuten der stromhemmende Effekt eintrat. 
MANT-GTPS entwickelte keinen signifikanten Stromanstieg und war den Kontroll-
messungen ähnlich, was bisher publizierten Ergebnissen entspricht.  
 
Alle MANT-Nukleotide haben eine hemmende Wirkung auf den basalen ICa,L, allerdings ist 
die Gesamtinhibition im Vergleich zur Kontrolle gering oder gar nicht erkennbar. Eine 
mögliche Erklärung wäre, dass MANT-Nukleotide neben der AC-Inhibition auch andere 
Zielproteine mehr oder weniger stark aktivieren bzw. inhibieren. Der Einsatz von MANT-
Nukleotiden sollte sich auf die Nutzung als Fluoreszenssonden, Liganden zur 
kristallographischen Strukturanalyse, beziehungsweise als Enzyminhibitoren beschränken. 
Denn sie eignen sich gut zur Analyse molekularer Wechselwirkungen von rekombinanten 
und/oder aufgereinigten nukleotid-bindendenden Proteinen. Die bisherig gewonnenen 
Ergebnisse lassen sich aber durchaus für die Synthese von membrangängigen, selektiveren 
AC 5 - Inhibitoren für die Entwicklung neuer Arzneistoffe, z.B. zur Therapie der Herz-
insuffizienz nutzen. In einem nächsten Schritt wäre es außerdem sehr wichtig, die 
unspezifischen Aktivierungs- bzw. Hemmeigenschaften der MANT-Nukleotide herauszu-
arbeiten.  
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8. Supplementary Data 
8.1. Western blot 
 
 Sample preparation and SDS-PAGE (2.2.1.9) 
 Transfer of proteins to nitrocellulose membrane (0.45 µm) 
 
1. Fresh preparation of blotting buffer (1.0 L / buffer tank) 
Per gel holder cassette: two foam pads, four sheets of filter paper and one 
nitrocellulose membrane – soaking in buffer 
Place on the black side of the gel holder cassette (not the clear side!!!): one foam pad, 
two sheets of filter paper 
2. Remove one side of the gel cassette, cut off the loading gel from the separating gel  
3. Soak the gel with water until it does not stick to the gel cassette anymore and can be 
moved to the filter paper 
 place the nitrocellulose membrane on top of the gel 
4. Place two filter papers on top of the membrane, removal of air bubbles with a pen  
Place one foam pad on top of the filter papers 
Close the gel holder cassette and put it with the black side to the black side of the 
electrophoresis blotting module 
5. Blotting at 4°C (in refrigerator) for 120 min, Power Pac basic power supply: 0.15 A  
 
 Blocking unspecific binding 
1. Fresh preparation of 1x TBS-T buffer (Tween 0.1% m/v) 
Dilute 5 g skimmed milk in 100 ml TBS-T buffer (5% m/v) 
2. Open the gel holder cassette, remove the membrane; 
Check blotting result by staining membrane with Ponceau S 0.1% (m/v) for 1 min. 
Cleaning with H2Odest. 
3. Incubate membrane 1 – 2 h in 5% (m/v) skimmed milk (TBS-T) on a shaker 
4. Remove milk and wash membrane 2x 5 - 10 min in TBS-T buffer (without milk!) 
 
 Detection of proteins via Chemiluminescence 
1. Primary antibody in TBS-T, containing sodium azide 0.05% (m/v) and BSA 1% (m/v) 
(10 - 20 ml solution of 1st antibody in a 50 ml Falcon tube, storage in refrigerator)  
2. Take nitrocellulose membrane and place it in 50 ml Falcon tube 
3. Incubate overnight at 4°C (cold room) using a vertical rotation mixer 
4. Remove membrane from 50 ml Falcon tube and wash 3x 15 min in TBS-T buffer 
5. Dilute secondary antibody in 5% skimmed milk (1:1000) 
Place membrane on parafilm in a Petri dish (no airbubbles) and soak it with 2nd 
antibody solution ( 4 ml), incubate 1 h at room temperature 
6. Remove milk and wash 3x 15 min in TBS-T buffer 
 
 Chemiluminescence 
1. Drain membrane on a filter paper and put it on a Petri dish (no airbubbles!)    
 membrane should not be wet anymore 
2. Take 2 ml of solution 1 and 2 from ECL-Kit  (4 ml / membrane), mix it and put it on top 
of the membrane for 1 min 
3. Drain membrane on filter paper and put it between two plastic foils, remove ECL rest 
4. Put the plastic foil in a X-ray film cassette for  1 min (depends on amount of protein) 
5. Develop film with X-ray film processor 
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8.1.1. VC1 purification 
  
Supplementary Figure 1. 
Western Blot of VC1 
protein detected with HIS-
antibody. 
The protein is expressed with 
a hexahistidine tag.  
Lane 7 is the protein standard 
and lanes 8-13 show 
collected fractions after ion 
exchange. 
 
8.1.2. Gs purification 
 
Supplementary Figure 2. 
Lysis and purification of Gs 
with Ni-NTA column. 
A. Western Blot of Gs with HIS-
Antibody, in comparison to the 
Coomassie stained SDS-PAGE, 
illustrated in B. 
Lane 
1 Pellet 
2 Lysate 
3 Load I 
4 Load II 
5 Wash 
6 Standard 
7 Fraction 1 
8 Fraction 2 
9 Fraction 6 
10 Fraction 10 
 
Gs is eluted at  46 kDa and 
indicated in the SDS-PAGE by a 
black arrow.   
 B  
B 
A 
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8.2. Protein purification of VC1 
 
 
 
Supplementary Figure 3. Chromatogram of VC1 purification. The figure shows the elution of VC1 from Mono S column using a gradient to 
NaCl 1M (brown straight line). The yellow peak represents VC1, also indicated in the corresponding SDS-PAGE gel (fractions 25-31). 
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8.3. Gel filtration of AC-complex with 6-Acetyl-7-Deacetyl-FS 
 
 
Supplementary Figure 4. Size exclusion chromatography of Gs-stimulated VC1/IIC2 (K1014N) complex with FS analog. Chromatogram and the gel 
show clearly that the complex was formed without FS, but with the help of 6-acetyl-7-deacetyl-FS. However, we never obtained crystals with FS analogs. 
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8.4. Crystal tray preparation 
 
TRAY NAME: __VC1/IIC2/Gs/FS__# 5      TEMPERATURE:  ____  4 / 12 / 16 / 20
oC 
DATE: ________03/21/2008___ BUFFER:          __HEPES buffer pH 8.0 
ADDITIVE: ______non________ SEEDING:  Y  /  N  FROM: ____________ 
PROTEIN(S):    complex of 03/19/2008 CONCENTRATION:       9 mg/ml 
 1 2 3 4 5 6 
A 
7.0% (v/v) PEG 8K    
50% (v/v) PEG 8K 140 µl 
5 M NaCl       100 µl 
1 M MES pH 5.4 100 µl 
dd water    660 µl 
7.2% (v/v) PEG 8K   
 50% (v/v) PEG 8K 144 µl 
5 M NaCl         100 µl 
1 M MES pH 5.4 100 µl 
dd water    656 µl 
7.4% (v/v) PEG 8K    
50%(v/v) PEG 8K  148 µl 
5 M NaCl      100 µl 
1 M MES pH 5.4 100 µl 
dd water    652 µl 
7.6% (v/v) PEG 8K    
50% (v/v) PEG 8K 152 µl 
5 M NaCl      100 µl 
1 M MES pH 5.4 100 µl 
dd water    648 µl 
7.8% (v/v) PEG 8K    
50% (v/v) PEG 8K 156 µl 
5 M NaCl      100 µl 
1 M MES pH 5.4 100 µl 
dd water    644 µl 
8.0% (v/v) PEG 8K    
50%(v/v) PEG 8K 160 µl 
5 M NaCl      100 µl 
1 M MES pH 5.4 100 µl 
dd water    640 µl 
B 
7.0% (v/v) PEG 8K    
50% (v/v) PEG 8K 140 µl 
5 M NaCl       100 µl 
1 M MES pH 5.5 100 µl 
dd water    660 µl 
7.2% (v/v)  PEG 8K 
50%(v/v) PEG 8K  144 µl 
5 M NaCl      100 µl 
1 M MES pH 5.5 100 µl 
dd water    656 µl 
7.4% (v/v) PEG 8K    
50% (v/v) PEG 8K 148 µl 
5 M NaCl      100 µl 
1 M MES pH 5.5 100 µl 
dd water    652 µl 
7.6% (v/v) PEG 8K    
50% (v/v) PEG 8K 152 µl 
5 M NaCl      100 µl 
1 M MES pH 5.5 100 µl 
dd water    648 µl 
7.8% (v/v) PEG 8K    
50% (v/v) PEG 8K 156 µl 
5 M NaCl      100 µl 
1 M MES pH 5.5 100 µl 
dd water    644 µl 
8.0% (v/v) PEG 8K    
50% (v/v) PEG 8K 160 µl 
5 M NaCl      100 µl 
1 M MES pH 5.5 100 µl 
dd water    640 µl 
C 
7.0% (v/v) PEG 8K    
50% (v/v) PEG 8K 140 µl 
5 M NaCl       100 µl 
1 M MES pH 5.6 100 µl 
dd water    660 µl 
7.2% (v/v) PEG 8K  
50% (v/v) PEG 8K  144 µl 
5 M NaCl      100 µl 
1 M MES pH 5.6 100 µl 
dd water    656 µl 
7.4% (v/v) PEG 8K    
50% (v/v) PEG 8K 148 µl 
5 M NaCl      100 µl 
1 M MES pH 5.6 100 µl 
dd water    652 µl 
7.6% (v/v) PEG 8K    
50% (v/v) PEG 8K 152 µl 
5 M NaCl      100 µl 
1 M MES pH 5.6 100 µl 
dd water    648 µl 
7.8% (v/v) PEG 8K    
50% (v/v) PEG 8K 156 µl 
5 M NaCl      100 µl 
1 M MES pH 5.6 100 µl 
dd water    644 µl 
8.0% (v/v) PEG 8K    
50% (v/v) PEG 8K 160 µl 
5 M NaCl      100 µl 
1 M MES pH 5.6 100 µl 
dd water    640 µl 
D 
7.0% (v/v) PEG 8K    
50% (v/v) PEG 8K 140 µl 
5 M NaCl       100 µl 
1 M MES pH 5.7 100 µl 
dd water    660 µl 
7.2% (v/v) PEG 8K    
50% (v/v) PEG 8K  144 µl 
5 M NaCl      100 µl 
1 M MES pH 5.7 100 µl 
dd water    656 µl 
7.4% (v/v) PEG 8K    
50% (v/v) PEG 8K 148 µl 
5 M NaCl      100 µl 
1 M MES pH 5.7 100 µl 
dd water    652 µl 
7.6% (v/v) PEG 8K    
50% (v/v) PEG 8K 152 µl 
5 M NaCl      100 µl 
1 M MES pH 5.7 100 µl 
dd water    648 µl 
7.8% (v/v) PEG 8K    
50% (v/v) PEG 8K  156 µl 
5 M NaCl      100 µl 
1 M MES pH 5.7 100 µl 
dd water    644 µl 
8.0% (v/v) PEG 8K    
50% (v/v) PEG 8K 160 µl 
5 M NaCl      100 µl 
1 M MES pH 5.7 100 µl 
dd water    640 µl 
 
Supplementary Figure 5. The table illustrates a 24 well plate used for crystallization. Each well contains 1 ml of reservoir solution, containing PEG, NaCl and MES buffer. 
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